

1 **Membrane-type 1 matrix metalloproteinase (MMP-14) modulates tissue**  
2 **homeostasis by a non-proteolytic mechanism**

3

4 Mukundan Attur <sup>1‡</sup>, Cuijie Lu <sup>1‡</sup>, Xiaodong Zhang <sup>2</sup>, Cassidy Alexandre <sup>2</sup>, Cristina Valacca  
5 <sup>2</sup>, Shuai Zheng <sup>2</sup>, Sarina Meikle <sup>2</sup>, Branka Brukner Dabovic <sup>3</sup>, Evelyne Tassone <sup>2</sup>, Qing  
6 Yang <sup>1</sup>, Victoria Kolupaeva <sup>4</sup>, Shoshana Yakar <sup>5</sup>, Steven Abramson <sup>1</sup> and Paolo Mignatti  
7 <sup>1,2,3, \*</sup>

8

9 ‡ Equal contribution

10

11 <sup>1</sup> Department of Medicine, Division of Rheumatology, <sup>2</sup> Department of Cardiothoracic  
12 Surgery, <sup>3</sup> Department of Cell Biology, <sup>4</sup> Department of Microbiology, NYU School of  
13 Medicine, 550 First Avenue, New York, NY 10016, USA; <sup>5</sup> Department of Basic Science  
14 & Craniofacial Biology, NYU College of Dentistry, 345 E. 24th Street, New York, NY  
15 10010.

16 Running title: *Non-proteolytic roles of MT1-MMP in vivo*

17 \* To whom correspondence should be addressed: Paolo Mignatti, NYU School of  
18 Medicine, Department of Medicine, Division of Rheumatology, 301 East 17th Street, Suite  
19 1612A, New York, NY 10003, USA. E-mail: [mignap01@nyumc.org](mailto:mignap01@nyumc.org)

20

21 **Keywords:** matrix metalloproteinases; skeletal stem cells; osteogenesis;  
22 chondrogenesis; adipogenesis; intracellular signaling

23

1 **ABSTRACT**

2 Membrane-type 1 matrix metalloproteinase (MT1-MMP, MMP-14), a transmembrane  
3 proteinase with a short cytoplasmic tail, is a major effector of extracellular matrix (ECM)  
4 remodeling. Genetic silencing of MT1-MMP in mouse (*Mmp14*<sup>-/-</sup>) and man causes  
5 dwarfism, osteopenia, generalized arthritis and lipodystrophy. These abnormalities have  
6 been ascribed to defective collagen turnover. We have previously shown non-proteolytic  
7 functions of MT1-MMP mediated by its cytoplasmic tail, where the unique tyrosine (Y573)  
8 controls intracellular signaling. Mutation of Y573 (Y573D) blocks signaling without  
9 affecting proteolytic activity. Here we report that a mouse with the MT1-MMP Y573D  
10 mutation (*Mmp14*<sup>Y573D/Y573D</sup>) shows abnormalities similar to those of *Mmp14*<sup>-/-</sup> mice.  
11 Skeletal stem cells (SSC) of *Mmp14*<sup>Y573D/Y573D</sup> mice show defective differentiation  
12 consistent with the mouse phenotype, which is rescued by wild-type SSC transplant.  
13 These results provide the first *in vivo* demonstration that MT1-MMP, an ECM-degrading  
14 proteinase, modulates bone, cartilage and fat homeostasis by controlling SSC  
15 differentiation through a mechanism independent of proteolysis.

16

## 1 INTRODUCTION

2 Membrane-type 1 matrix metalloproteinase (MT1-MMP, or MMP-14), the product of  
3 the gene *MMP14*, is a cell-membrane-bound proteinase with an extracellular catalytic site  
4 and a 20-amino acid cytoplasmic tail (Itoh, 2015; Sato et al., 1994). It degrades a variety  
5 of ECM components and is expressed by a wide array of normal and tumor cells. Notably,  
6 MT1-MMP is the only MMP whose genetic deficiency in the mouse results in severe  
7 phenotypes and early death. These features have implicated MT1-MMP as an important  
8 component of the proteolytic mechanisms of physiological and pathological processes  
9 including bone, cartilage and adipose tissue homeostasis, as well as tumor invasion,  
10 angiogenesis and metastasis. The analysis of the phenotype of mice genetically deficient  
11 in MT1-MMP (*Mmp14*<sup>-/-</sup>) has shown key roles of this proteinase in the postnatal  
12 development and growth of cartilage, bone and adipose tissue. *Mmp14* deficiency in the  
13 mouse results in dwarfism, severe osteopenia, generalized arthritis and lipodystrophy,  
14 among other abnormalities (Chun et al., 2006; Chun & Inoue, 2014; Holmbeck et al.,  
15 1999; Zhou et al., 2000). In humans a mutation of *MMP14* causes multicentric osteolysis  
16 and arthritis disease, or Winchester syndrome, which recapitulates much of the  
17 phenotype of the *Mmp14*<sup>-/-</sup> mouse (Evans et al., 2012). Conditional *Mmp14* knockout in  
18 uncommitted skeletal stem cells (SSC, also referred to as mesenchymal stem cells), the  
19 common progenitors of osteoblasts, chondrocytes and adipocytes, recapitulates the  
20 skeletal phenotype of the global *Mmp14* knockout mouse (Y. Tang et al., 2013).  
21 Conversely, unlike global *Mmp14* deficiency conditional *Mmp14* knockout in SSC results  
22 in thickening of articular cartilage and increased bone marrow (BM)-associated fat but  
23 decreased subcutaneous fat, which derives from distinct progenitor cells (Chun et al.,  
24 2006; Gupta et al., 2012; Tran et al., 2012). In light of the fundamental role of MT1-MMP

1 in ECM degradation, it has been proposed that the phenotypes of *Mmp14*<sup>-/-</sup> mice result  
2 from defective collagen turnover (Chun et al., 2006; Chun & Inoue, 2014; Holmbeck et  
3 al., 1999; Zhou et al., 2000).

4 However, a number of *in vitro* studies have provided evidence for a variety of non-  
5 proteolytic roles of MT1-MMP. We have previously shown that the MT1-MMP cytoplasmic  
6 tail activates Ras-ERK1/2 and Akt signaling by a non-proteolytic mechanism that controls  
7 cell proliferation, migration and apoptosis *in vitro*, as well as tumor growth *in vivo*  
8 (D'Alessio et al., 2008; Valacca et al., 2015). Signaling is activated in a dose- and time-  
9 dependent manner by MT1-MMP binding of low nanomolar concentrations of tissue  
10 inhibitor of metalloproteinases-2 (TIMP-2), a physiological protein inhibitor of MT1-MMP.  
11 Signaling activation is also mediated by mutant TIMP-2 lacking MMP inhibitory activity  
12 (Ala+ TIMP-2) as well as by mutant MT1-MMP devoid of proteolytic activity (MT1-MMP  
13 E240A), showing that the signaling mechanism is proteolysis-independent. We also  
14 showed that MT1-MMP signaling requires the unique tyrosine (Y573) in the cytoplasmic  
15 tail, which is phosphorylated by Src and LIM1 kinases (Lagoutte et al., 2016; Nyalendo et  
16 al., 2007), and that Y573 substitution with aspartic acid (Y573D), a negatively charged  
17 amino acid like phosphotyrosine, abrogates MT1-MMP-mediated activation of Ras-  
18 ERK1/2 (D'Alessio et al., 2008). Other groups have subsequently found that Y573  
19 controls a variety of signaling pathways and cell functions *in vitro* (Annabi et al., 2009;  
20 Belkaid et al., 2007; Gonzalo et al., 2010; Proulx-Bonneau et al., 2011; Sakamoto & Seiki,  
21 2009; Sina et al., 2010). Y573 is required for activation of the small GTPase Rac1  
22 (Gonzalo et al., 2010), controls macrophage migration and infiltration at sites of  
23 inflammation (Gonzalo et al., 2010; Sakamoto & Seiki, 2009), as well as MT1-MMP  
24 interaction with Src and focal adhesion kinase (FAK) (Y. Wang & McNiven, 2012).



1           Based on these observations, we generated a mutant mouse with the Y573D  
2 substitution in the cytoplasmic tail of MT1-MMP (MT1-MMP Y573D). Here we report that  
3 this mouse shows abnormalities in postnatal bone, cartilage and adipose tissue  
4 development and growth that partly recapitulate the phenotype of the *MMP14*<sup>-/-</sup> mouse.  
5 These phenotypes derive from dysregulation of BM SSC differentiation, and are rescued  
6 by wild-type (wt) BM transplant.

7

## 1 RESULTS

### 2 ***Generation and characterization of MT1-MMP Y573D mice***

3 Mice heterozygous ( $Mmp^{Y573D/wt}$ ) or homozygous ( $Mmp^{Y573D/Y573D}$ ) for the MT1-MMP  
4 Y573D mutation, generated as described in Materials and Methods (Fig. 1), were  
5 macroscopically indistinguishable from  $Mmp14^{wt/wt}$  mice at birth. However, after the first  
6 2 months  $Mmp14^{Y573D/wt}$  and  $Mmp14^{Y573D/Y573D}$  mice showed a slightly lower growth rate  
7 than their  $Mmp14^{wt/wt}$  littermates (Fig. 2 A). In mice older than 3 months the weight of  
8  $Mmp14^{Y573D/Y573D}$  male and female mice was 15 % lower than that of age- and sex-  
9 matched  $Mmp14^{wt/wt}$  littermates (Fig. 2 B).

10 By Western blotting (Fig. 2 C),  $Mmp14^{Y573D/Y573D}$  mice showed tissue levels of MT1-  
11 MMP comparable to that of  $Mmp14^{wt/wt}$  mice. Consistent with previous findings (Uekita et  
12 al., 2001), primary fibroblasts from 3-weeks old  $Mmp14^{Y573D/Y573D}$  mice and  $Mmp14^{wt/wt}$   
13 littermates had similar MT1-MMP proteolytic activity (Fig. 2 D). Thus, the Y573D mutation  
14 did not significantly alter the plasma membrane expression or proteolytic activity of MT1-  
15 MMP. In addition, in agreement with our previous findings (D'Alessio et al., 2008; Valacca  
16 et al., 2015), primary fibroblasts from  $Mmp14^{Y573D/Y573D}$  mice showed strongly reduced  
17 ERK1/2 and Akt activation in response to exogenous TIMP-2 relative to  $Mmp14^{wt/wt}$  cells  
18 (Fig. 2 E).

19

### 20 ***MT1-MMP Y573D mice show structural and gene expression abnormalities in bone,*** 21 ***articular cartilage and adipose tissue***

22 A striking phenotype of  $Mmp14^{-/-}$  mice is the dramatically decreased length of long  
23 bones, with severe osteopenia and arthritis (Holmbeck et al., 1999; Zhou et al., 2000). At

1 5 months of age the femurs of *Mmp14*<sup>Y573D/Y573D</sup> mice were only ~ 5% shorter than those  
2 of *Mmp14*<sup>wt/wt</sup> mice (14.81 ± 0.1519 mm vs. 15.61 ± 0.0619 mm; n=10; p = 0.0001).  
3 However, cortical bone thickness at the femur mid-diaphysis was markedly decreased  
4 (20-25%) in *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice (Fig. 3 A), a finding consistent with the  
5 osteopenia of the *Mmp14*<sup>-/-</sup> mouse (Holmbeck et al., 1999; Zhou et al., 2000). Conversely,  
6 unlike *Mmp14*<sup>-/-</sup> mice, which have reduced trabecular bone, and in the homozygous but  
7 not in the heterozygous state (Holmbeck et al., 1999; Zhou et al., 2000), femurs and tibias  
8 showed significantly increased (40-50%) trabecular bone in both *Mmp14*<sup>Y573D/Y573D</sup> and  
9 *Mmp14*<sup>Y573D/wt</sup> mice relative to age- and sex-matched *Mmp14*<sup>wt/wt</sup> mice (Fig. 3 B - D). This  
10 effect was accompanied by increased TRAP-positive osteoclasts (Fig. 3 – supplement 1),  
11 indicating enhanced bone remodeling, a feature also observed in *Mmp14*<sup>-/-</sup> mice  
12 (Holmbeck et al., 1999).

13 Gene expression profiling of bone from *Mmp14*<sup>Y573D/Y573D</sup> mice (Fig. 3 E) showed 76  
14 genes significantly (p ≤ 0.05) up- or downregulated relative to *Mmp14*<sup>wt/wt</sup> littermates. A  
15 subset of 17 of these transcripts were upregulated 2-fold or more, and 26 were  
16 downregulated 2-fold or more. Consistent with the morphometric analyses, gene ontology  
17 analysis showed highly significant enrichment for biological processes related to  
18 osteoblast differentiation, bone remodeling, ossification and bone growth (Fig. 3 F).

19 The knee joints of 2-month old mice showed several abnormalities. Both  
20 *Mmp14*<sup>Y573D/wt</sup> and *Mmp14*<sup>Y573D/Y573D</sup> mice displayed marked thinning of articular cartilage  
21 (Fig. 4 A top panels, and B) with loss of proteoglycans (Fig. 4 C and D), clustering and  
22 cloning of chondrocytes (Fig. 4 A lower panels), classic histologic features of the articular  
23 cartilage degeneration associated with human osteoarthritis (OA) and surgical models of

1 OA in mice. The knee cartilage of 2-year old mice also showed fissures, chondrocyte  
2 clustering and cloning, abnormalities typical of ageing-associated cartilage degeneration  
3 that were not observed in age- and sex-matched *Mmp14<sup>wt/wt</sup>* mice (Fig. 4 E).

4 RNA-Seq analysis of the transcriptome of cartilage from *Mmp14<sup>Y573D/Y573D</sup>* mice (Fig.  
5 5 A) showed significant dysregulation of the expression of 1,549 genes relative to  
6 *Mmp14<sup>wt/wt</sup>* mice ( $p \leq 0.05$ ). Of these genes, 694 were upregulated 2-fold or more, and 92  
7 were downregulated 2-fold or more. Gene ontology analysis (Fig. 5 B) showed highly  
8 significant enrichment for biological processes related to extracellular matrix  
9 homeostasis, cartilage development and chondrocyte differentiation. As these biological  
10 processes are strongly dysregulated in human OA, we analyzed the transcriptome of  
11 *Mmp14<sup>Y573D/Y573D</sup>* cartilage for expression of genes involved in human OA (Fig. 5 C). Gene  
12 expression profiling of human OA cartilage has revealed 1,423 genes significantly ( $p \leq$   
13 0.05) up- or downregulated relative to normal cartilage, 111 of which are strongly up- or  
14 downregulated ( $\geq 2$ -fold or  $\leq 2$ -fold) (Geyer et al., 2009; Karlsson et al., 2010). We found  
15 that 48 of these 111 OA-associated genes are also strongly regulated in *Mmp14<sup>Y573D/Y573D</sup>*  
16 mouse cartilage, including all the genes for collagens and other ECM proteins  
17 upregulated in human OA, ECM-degrading proteinases, as well as genes involved in cell  
18 metabolism (Figure 5 D). Thus, consistent with its histological features, *Mmp14<sup>Y573D/Y573D</sup>*  
19 joint cartilage showed significant gene expression similarity to human OA.

20 Sections of the long bones of adult *Mmp14<sup>Y573D/wt</sup>* and *Mmp14<sup>Y573D/Y573D</sup>* mice also  
21 showed marked decrease in BM-associated fat relative to *Mmp14<sup>wt/wt</sup>* littermates (Fig. 6  
22 A and B). A similar reduction was apparent in all other fat pads, as evidenced by ~ 50%  
23 decrease in body adiposity by DEXA analysis and in the gonadal fat of *Mmp14<sup>Y573D/Y573D</sup>*

1 mice relative to age- and sex-matched *Mmp14*<sup>wt/wt</sup> littermates (Fig. 6 C and D). This effect  
2 was observed in mice of both sexes and ages ranging 3 months to 2 years (Fig. 6 -  
3 supplements 1 and 2). Histological analysis of abdominal and subcutaneous WAT from  
4 *Mmp14*<sup>Y573D/Y573D</sup> mice revealed marked decrease in the size of adipocytes (Fig. 7 A, C  
5 and supplement 1). These findings are consistent with the lipodystrophy of *Mmp14*<sup>-/-</sup> mice  
6 (Chun et al., 2006; Chun et al., 2010). In contrast, the brown adipose tissue (BAT) of  
7 *Mmp14*<sup>Y573D/Y573D</sup> mice showed pronounced adipocyte hypertrophy, with decreased  
8 expression of the characteristic marker of BAT, uncoupling protein-1 (UCP-1; Fig. 7 B  
9 and supplement 2).

10 The transcriptome of abdominal WAT from *Mmp14*<sup>Y573D/Y573D</sup> mice (Fig. 7 D) showed  
11 significant ( $p \leq 0.05$ ) up- or downregulation of the expression of 151 genes, relative to  
12 *Mmp14*<sup>wt/wt</sup> mice. Gene ontology analysis (Fig. 7 E) identified highly significant enrichment  
13 for biological processes including control of small molecule synthesis, lipid and fatty acid  
14 metabolism, response to corticosteroids, and extracellular matrix homeostasis. Some of  
15 these pathways are also overrepresented in *Mmp14*<sup>+/-</sup> mice on a high-fat diet (Chun et  
16 al., 2010). Moreover, similar to *Mmp14*<sup>+/-</sup> mice, *Mmp14*<sup>Y573D/Y573D</sup> mice were protected  
17 from body weight gain induced by high-fat diet (Fig. 7 – supplement 3).

18 In addition to reduced WAT, *Mmp14*<sup>Y573D/Y573D</sup> mice showed strongly decreased  
19 fasting levels of plasma insulin relative to age- and sex-matched *Mmp14*<sup>wt/wt</sup> littermates,  
20 with normoglycemia and normal food consumption (Fig. 8 and supplement 1).  
21 *Mmp14*<sup>Y573D/Y573D</sup> and *Mmp14*<sup>wt/wt</sup> mice also had comparable levels of ACTH, which  
22 controls adipose tissue metabolism, and leptin, a hormone secreted predominantly by  
23 adipose tissue. Conversely, *Mmp14*<sup>Y573D/Y573D</sup> mice had extremely low serum levels of the

1 inflammatory cytokines interleukin-6 (IL-6), monocyte chemoattractant protein 1/  
2 chemokine (C-C motif) ligand 2 (MCP-1/CCL2), and IL-10 relative to age- and sex-  
3 matched *Mmp14*<sup>wt/wt</sup> mice (Fig. 8).

4

5 ***MT1-MMP Y573D expression alters skeletal stem cell proliferation and apoptosis,***  
6 ***and skews differentiation from chondro- and adipogenesis towards osteogenesis***

7 The observation that the phenotype of *Mmp14*<sup>Y573D/Y573D</sup> mice involves abnormalities  
8 of bone, cartilage and adipose tissue indicated that the MT1-MMP Y573D mutation might  
9 affect the differentiation of SSC, the common progenitor cells of these tissues. Therefore,  
10 we isolated SSC from the BM of *Mmp14*<sup>wt/wt</sup> and *Mmp14*<sup>Y573D/Y573D</sup> littermates, and  
11 characterized them *in vitro* (Fig. 9). *Mmp14*<sup>Y573D/Y573D</sup> SSC contained fewer colony-  
12 forming units-fibroblasts (CFU-F) than *Mmp14*<sup>wt/wt</sup> SSC ( $1.5 \times 10^{-6}$  vs.  $4.5 \times 10^{-6}$ ,  
13 respectively), formed much smaller colonies (Fig. 9 A), and showed remarkably lower  
14 proliferation rate and higher apoptosis index (Fig. 9 B and C). RNA-Seq analysis (Fig. 9  
15 D) showed 486 genes significantly dysregulated ( $p \leq 0.05$ ) in *Mmp14*<sup>Y573D/Y573D</sup> vs.  
16 *Mmp14*<sup>wt/wt</sup> SSC. Gene ontology analysis (Fig. 9 E) revealed highly significant enrichment  
17 of genes involved in DNA synthesis, cell cycle regulation and response to DNA damage,  
18 indicating dysregulation of cell proliferation and survival.

19 We then induced BM-derived SSC from *Mmp14*<sup>Y573D/Y573D</sup> and *Mmp14*<sup>wt/wt</sup> littermates  
20 to differentiate *in vitro* into the osteoblast, chondrocyte and adipocyte lineages. qPCR  
21 analysis of the expression of lineage-specific markers showed dramatic increase in  
22 osteogenesis (Fig. 9 F, top panel), and marked decrease in chondrocyte and adipocyte  
23 differentiation (Fig. 9 F, middle and bottom panels, respectively) in *Mmp14*<sup>Y573D/Y573D</sup> vs.

1 *Mmp14*<sup>wt/wt</sup> SSC. The expression levels of wt MT1-MMP and MT1-MMP Y573D did not  
2 change during osteoblast differentiation, and on day 17 comparable levels of MT1-MMP  
3 mRNA were expressed by *Mmp14*<sup>wt/wt</sup> and *Mmp14*<sup>Y573D/Y573D</sup> SSC (Fig. 9 F; top panel).  
4 Conversely, in agreement with previous reports (Y. Tang et al., 2013), MT1-MMP  
5 expression decreased by ~ 80% during chondrocyte differentiation in both *Mmp14*<sup>wt/wt</sup> and  
6 *Mmp14*<sup>Y573D/Y573D</sup> SSC, and on day 17 *Mmp14*<sup>Y573D/Y573D</sup> cells expressed significantly  
7 lower MT1-MMP levels than *Mmp14*<sup>wt/wt</sup> SSC (Fig. 9 F, middle panel).

8 To confirm that the differences in BM-SSC differentiation between *Mmp14*<sup>wt/wt</sup> and  
9 *Mmp14*<sup>Y573D/Y573D</sup> mice are mediated by the MT1-MMP Y573D mutation, we transfected  
10 wt MT1-MMP or MT1-MMP Y573D cDNA into mouse C3H10T1/2 cells, which are  
11 functionally similar to SSC (Q. Q. Tang et al., 2004), and analyzed their capacity to  
12 differentiate into osteoblasts, chondrocytes and adipocytes (Fig. 9 G) by lineage-specific  
13 staining. Consistent with the results obtained with primary BM-derived SSC, C3H10T1/2  
14 cells transfected with MT1-MMP Y573D showed markedly increased osteogenesis, and  
15 decreased chondro- and adipogenesis relative to wt MT1-MMP transfectants (Fig. 9 G).  
16 Therefore, in both BM-derived SSC and C3H10T1/2 cells MT1-MMP Y573D expression  
17 skewed differentiation towards the osteogenic lineage.

18

19 ***The bone and fat phenotypes of *Mmp14*<sup>Y573D/Y573D</sup> mice are rescued by wt BM***  
20 ***transplant***

21 These results indicated that the bone, cartilage and fat phenotypes of  
22 *Mmp14*<sup>Y573D/Y573D</sup> mice result from a defect in SSC. Therefore, we hypothesized that the  
23 phenotypes of these mice could be rescued by transplantation of *Mmp14*<sup>wt/wt</sup> BM; and,

1 *vice versa*, transplantation of *Mmp14*<sup>Y573D/Y573D</sup> BM could transfer the phenotype to  
2 *Mmp14*<sup>wt/wt</sup> mice. We therefore transplanted 3- and 5-month old mice with BM from mice  
3 of the same age and the opposite genotype or, as controls, from mice of the same age  
4 and genotype, and analyzed their phenotypes two months later.

5 We characterized the trabecular and cortical bone of the femurs of the transplanted  
6 mice by microCT analysis (Fig. 10). The results showed that transplantation of *Mmp14*<sup>wt/wt</sup>  
7 BM had no effect on the cortical bone of *Mmp14*<sup>Y573D/Y573D</sup> mice transplanted at 3 months  
8 or 5 months of age (Fig. 10 A and supplement 1); however, it completely rescued their  
9 trabecular bone phenotype (Fig. 10 B and supplement 1). Conversely, transplantation of  
10 *Mmp14*<sup>Y573D/Y573D</sup> BM did not transfer the trabecular or cortical bone phenotype to wt mice.

11 We also found that BM transplant induced no significant changes in articular  
12 cartilage thickness relative to the original phenotype of the transplant recipients in this  
13 short-term study (data not shown).

14 Similarly to the bone phenotype, *Mmp14*<sup>wt/wt</sup> BM transplant completely rescued the  
15 decrease in fat mass of *Mmp14*<sup>Y573D/Y573D</sup> mice, but *Mmp14*<sup>Y573D/Y573D</sup> BM did not transfer  
16 the adipose tissue phenotype to *Mmp14*<sup>wt/wt</sup> mice (Fig. 11 A). However, consistent with  
17 the existence of BM-derived adipocyte precursors able to colonize peripheral WAT and  
18 BAT (Crossno et al., 2006), histological analysis of WAT and BAT from transplanted mice  
19 (Fig. 11 B and C) showed mixtures of normal and hypotrophic white adipocytes in both  
20 *Mmp14*<sup>wt/wt</sup> mice transplanted with *Mmp14*<sup>Y573D/Y573D</sup> BM and *Mmp14*<sup>Y573D/Y573D</sup> mice  
21 transplanted with *Mmp14*<sup>wt/wt</sup> BM. Conversely, BM recipients acquired the BAT phenotype  
22 of donor mice (Fig. 11 C).



1           The analysis of BM engraftment, described in Materials and Methods, showed  
2   virtually complete replacement of the recipient's BM with the donors' BM (Fig. 11  
3   supplement 1). The circulating blood cells of *Mmp14*<sup>Y573D/Y573D</sup> mice displayed no  
4   significant abnormalities and numbers comparable to those of *Mmp14*<sup>wt/wt</sup> mice, showing  
5   that the MT1-MMP Y573D mutation does not affect hematopoietic cells. Therefore, these  
6   results showed that the bone and fat phenotype of transplanted *Mmp14*<sup>Y573D/Y573D</sup> mice  
7   resulted from the transfer of SSC, and not from other BM cells.

8

## 1 DISCUSSION

2 MT1-MMP plays an important role in the postnatal development of a variety of  
3 tissues including bone, cartilage and fat. The striking abnormalities of *Mmp14*<sup>-/-</sup> mice –  
4 dwarfism, severe osteopenia, generalized arthritis, fibrosis and lipodystrophy - have been  
5 ascribed to impaired collagen turnover, which also plays a fundamental role in SSC  
6 differentiation and affects adipocyte development (Chun et al., 2006; Chun & Inoue, 2014;  
7 Holmbeck et al., 1999; Zhou et al., 2000). The data presented in this paper show that, in  
8 addition to its proteolytic activity, MT1-MMP contributes to bone, cartilage and adipose  
9 tissue homeostasis through a proteolysis-independent mechanism mediated by its  
10 cytoplasmic domain. This conclusion is based on the following observations.

11 We have previously shown that MT1-MMP activates ERK1/2 and Akt signaling upon  
12 binding of physiological concentrations of TIMP-2 (D'Alessio et al., 2008; Valacca et al.,  
13 2015). Signaling is activated by mutant MT1-MMP devoid of proteolytic activity (MT1-  
14 MMP E240A) or TIMP-2 lacking MMP inhibitory activity (Ala+ TIMP-2), and is blocked by  
15 the Y573D substitution in the MT1-MMP cytoplasmic tail. As this mutation does not  
16 significantly alter the cell surface expression or proteolytic activity of MT1-MMP (Uekita  
17 et al., 2001) (Fig. 2), these findings showed that MT1-MMP activation of ERK1/2 and Akt  
18 signaling is independent of its proteolytic activity and mediated by its cytoplasmic domain.

19 To investigate the physiological significance of our *in vitro* findings, we generated a  
20 mouse in which MT1-MMP activation of ERK1/2 and Akt is abrogated by the Y573D  
21 mutation. The data presented in this paper show that mice bearing this mutation present  
22 phenotypes that recapitulate those caused by *Mmp14* deficiency. The phenotypes of  
23 *Mmp14*<sup>Y573D/Y573</sup> mice appear to be milder than those of *Mmp14*<sup>-/-</sup> mice, indicating that

1 both the proteolytic and signaling functions of MT1-MMP are required for normal postnatal  
2 development and homeostasis. However, while comparing the phenotypes of  
3 *Mmp14*<sup>Y573D/Y573</sup> and *Mmp14*<sup>-/-</sup> mice provides information about the relative contribution of  
4 the proteolytic and non-proteolytic functions of MT1-MMP to postnatal development and  
5 tissue homeostasis, significant limitations must be considered. *Mmp14*<sup>-/-</sup> mice die within  
6 2 months of age (Holmbeck & al., 1999), whereas *Mmp14*<sup>Y573D/Y573</sup> mice have a normal  
7 life span and their phenotypes become apparent in animals older than 2 months. The  
8 global deficiency of *Mmp14* causes severe runting and wasting that ultimately lead to  
9 death. It is possible that the dramatic abnormalities of some tissues including cartilage  
10 and fat result from indirect effects. For instance, the generalized inflammatory state of  
11 *Mmp14*<sup>-/-</sup> mice (Shimizu-Hirota et al., 2012) may be the cause of, or contribute to their  
12 severe arthritis. Indeed, conditional *Mmp14* knockout in uncommitted SSC results in  
13 increased thickness of the articular cartilage in 3-month old mice (Y. Tang et al., 2013),  
14 in contrast with the reduced thickness and degeneration of *Mmp14*<sup>-/-</sup> and  
15 *Mmp14*<sup>Y573D/Y573D</sup> cartilage (Holmbeck & al., 1999).

16 Furthermore, the relative contribution of MT1-MMP proteolytic and signaling  
17 functions to postnatal development and homeostasis may vary at different stages of  
18 postnatal life. The lethality of *Mmp14* deficiency limits our understanding of the role of  
19 MT1-MMP to relatively early stages of postnatal development; in contrast, the normal life  
20 span of *Mmp14*<sup>Y573D/Y573</sup> mice affords studying the role of MT1-MMP in adult animals. Our  
21 finding that the phenotype of the *Mmp14*<sup>Y573D/Y573</sup> mouse becomes apparent in adult mice  
22 indicates that the proteolytic and the signaling function of MT1-MMP have predominant  
23 roles at different stages of postnatal development. The severe phenotype and early  
24 mortality of the *Mmp14*<sup>-/-</sup> mouse shows that MT1-MMP proteolytic activity has a

1 fundamental role at early stages. Conversely, silencing MT1-MMP signaling is compatible  
2 with normal development but results in altered tissue homeostasis in the adult animal.

3 Our analysis of the articular cartilage of *Mmp14*<sup>Y573D/Y573D</sup> mice showed signs of  
4 tissue degeneration similar to, but milder than that of *Mmp14*<sup>-/-</sup> mice. However, whereas  
5 *Mmp14*<sup>-/-</sup> mice have severe, acute arthritis (Holmbeck & al., 1999), the articular cartilage  
6 of *Mmp14*<sup>Y573D/Y573D</sup> mice shows histological signs and gene expression profile  
7 comparable to human OA, a chronic degenerative condition. The striking similarity of the  
8 gene expression profile of the articular cartilage of *Mmp14*<sup>Y573D/Y573D</sup> mice to that of human  
9 OA raises an interesting point about the role of MT1-MMP in articular cartilage  
10 homeostasis and the pathogenesis of OA. MT1-MMP expression decreases during  
11 chondrocyte differentiation, and in differentiated chondrocytes is ~ 80% lower than in  
12 undifferentiated SSC (Y. Tang et al., 2013). Consistent with this finding, *Mmp14*  
13 deficiency in uncommitted SSC results in increased differentiation into chondrocytes and  
14 thickening of articular cartilage (Y. Tang et al., 2013), suggesting that MT1-MMP  
15 expression contrasts normal chondrocyte development and articular cartilage  
16 homeostasis. Indeed, MT1-MMP is upregulated in OA cartilage relative to normal  
17 cartilage (Dreier et al., 2004; Kevorkian et al., 2004; Tchetina et al., 2005), indicating that  
18 MT1-MMP expression must be strictly controlled for normal cartilage homeostasis. In  
19 *Mmp14*<sup>Y573D/Y573D</sup> mice chondrocyte expression of MT1-MMP is lower than in *Mmp14*<sup>wt/wt</sup>  
20 mice (Fig. 9 F); however, their cartilage is thinner and presents signs of degeneration,  
21 showing that altering MT1-MMP signaling has a pathological effect even in the presence  
22 of low levels of MT1-MMP proteolytic activity. Thus, MT1-MMP signaling is required for  
23 articular cartilage homeostasis.

1 Our phenotypic analysis of *Mmp14*<sup>Y573D/Y573D</sup> mice showed significant abnormalities  
2 in WAT, consistent with the phenotype of *Mmp14*<sup>-/-</sup> mice and of mice with conditional  
3 *Mmp14* knockout in uncommitted SSC (Y. Tang et al., 2013). However, some differences  
4 are noteworthy. In contrast to WAT hypotrophy, we surprisingly found BAT hypertrophy  
5 in *Mmp14*<sup>Y573D/Y573</sup> mice, a finding at variance with the normal BAT of *Mmp14*<sup>-/-</sup> mice  
6 (Chun et al., 2006). Similarly, BM-associated WAT is decreased in *Mmp14*<sup>Y573D/Y573</sup> mice  
7 but increased in mice with conditional knockout of *Mmp14* in uncommitted SSC (Y. Tang  
8 et al., 2013) (unfortunately, the severe wasting and early death of *Mmp14*<sup>-/-</sup> mice preclude  
9 a reliable assessment of BM-associated fat, which typically develops with aging).  
10 However, while the SSC of conditional *Mmp14*<sup>-/-</sup> mice show increased adipocyte  
11 differentiation *in vitro* (Y. Tang et al., 2013), the SSC of *Mmp14*<sup>Y573D/Y573D</sup> mice show  
12 decreased adipocyte differentiation. MT1-MMP is a fundamental effector of adipocyte  
13 growth through collagen degradation, a process required for adipocyte increase in size  
14 (Chun et al., 2006; Chun & Inoue, 2014). However, *Mmp14*<sup>-/-</sup> mice have multiple, severe  
15 developmental and metabolic defects that can affect adipose tissue development  
16 indirectly. Our data show that *in vivo* MT1-MMP contributes to both WAT and BAT  
17 homeostasis by a proteolysis-independent mechanism mediated by its cytoplasmic tail.  
18 Several studies have shown the involvement of MT1-MMP in adipose tissue homeostasis  
19 (Chun et al., 2006; Feinberg et al., 2016; Fenech, Gavrilovic, Malcolm, et al., 2015;  
20 Fenech, Gavrilovic, & Turner, 2015), and genetic associations between MT1-MMP and  
21 obesity in humans have been reported (Chun et al., 2010). MT1-MMP has also been  
22 proposed to control metabolic balance (Mori et al., 2016), a function that could explain  
23 the WAT and BAT abnormalities of MT1-MMP Y573D mice. Understanding the

1 proteolysis-independent mechanism of MT1-MMP control of adipose tissue homeostasis  
2 can therefore have significant clinical and pharmacological implications.

3 The cortical bone of *Mmp14*<sup>Y573D/Y573</sup> mice shows a significant decrease in thickness,  
4 a phenotype similar to – if milder than - that caused by *Mmp14* deficiency. In contrast, the  
5 increased trabecular bone of *Mmp14*<sup>Y573D/Y573</sup> mice contrasts with the severe osteopenia  
6 of *Mmp14*<sup>-/-</sup> mice and mice with *Mmp14* knockout in uncommitted SSC (Holmbeck & al.,  
7 1999; Y. Tang et al., 2013). This discrepancy between the phenotypic effects of the MT1-  
8 MMP Y573D mutation and *Mmp14* deficiency suggests that the proteolytic and signaling  
9 functions of MT1-MMP can have opposing roles in bone physiology, and that a balance  
10 between the two functions is required for tissue homeostasis. Deletion of the gene  
11 abrogates both functions, whereas the MT1-MMP Y573D mutation only affects signaling,  
12 altering the balance between ECM proteolysis and intracellular signaling. Moreover, it  
13 should be noted again that the bone phenotype of the global or conditional *Mmp14*  
14 knockout in SSC can only be observed within the first two-three months of age, whereas  
15 the bone abnormalities of *Mmp14*<sup>Y573D/Y573</sup> mice become apparent in animals older than  
16 two months. It is possible that the proteolytic and signaling functions of MT1-MMP play  
17 different roles in bone modeling (postnatal development) and remodeling (adult life),  
18 respectively.

19 Consistent with their respective phenotypes, the BM-SSC of *Mmp14*<sup>Y573D/Y573D</sup> mice  
20 show increased osteoblast differentiation, and decreased chondrocyte and adipocyte  
21 differentiation. Our finding that the bone and adipose tissue phenotypes can be rescued  
22 by *Mmp14*<sup>wt/wt</sup> BM transplant shows that the *in vivo* effects of the MT1-MMP Y573D  
23 mutation result from dysregulation of SSC differentiation. Several considerations can

1 explain the failure of *Mmp14*<sup>Y573D/Y573D</sup> BM to transfer the mutant phenotypes to  
2 *Mmp14*<sup>wt/wt</sup> mice, as well as the incapacity of *Mmp14*<sup>wt/wt</sup> BM to rescue the cartilage  
3 phenotype of *Mmp14*<sup>Y573D/Y573D</sup> mice. *Mmp14*<sup>Y573D/Y573D</sup> SSC have significantly reduced  
4 proliferation and increased apoptosis relative to *Mmp14*<sup>wt/wt</sup> SSC (Fig. 9 A - C). We  
5 examined the phenotypes of the transplanted mice 2 months after the transplant. While  
6 hematopoietic cells from *Mmp14*<sup>Y573D/Y573D</sup> mice were able to efficiently repopulate the  
7 BM of wt mice – indeed, we found no peripheral blood abnormalities in *Mmp14*<sup>Y573D/Y573D</sup>  
8 mice – *Mmp14*<sup>Y573D/Y573D</sup> SSC might have required a longer time than wt cells for the  
9 phenotypic effects to become apparent. Similarly, BM transplant did not affect the cortical  
10 bone phenotype of *Mmp14*<sup>Y573D/Y573D</sup> mice. Cortical bone has a much slower turnover than  
11 trabecular bone (Clarke, 2008); therefore a longer time is required for its homeostasis to  
12 be altered. The failure of our BM transplant experiments to affect the articular cartilage  
13 phenotype is consistent with the absence of vascularization of this tissue. Indeed, no  
14 attempts at treating joint cartilage diseases by systemic stem cell administration have  
15 thus far been effective (Jevotovsky et al., 2018).

16 MT1-MMP is constitutively expressed in SSC and its levels are differentially  
17 modulated during osteogenic vs. chondrogenic/adipogenic differentiation (Y. Tang et al.,  
18 2013). The MT1-MMP Y573D mutation and *Mmp14* deficiency have opposing effects on  
19 SSC differentiation *in vitro*. *Mmp14* knockout in uncommitted SSC has no effect on their  
20 differentiation in 2D culture; however, it causes decreased osteogenesis and increased  
21 chondro- and adipogenesis in 3D collagen gel (Y. Tang et al., 2013). In contrast, in 2D  
22 culture MT1-MMP Y573D expression upregulates SSC differentiation into osteoblasts  
23 and downregulates chondrocyte and adipocyte differentiation (Fig. 9 F and G). While the  
24 *in vitro* differentiation of *Mmp14*<sup>Y573D/Y573D</sup> SSC and SSC with conditional *Mmp14*

1 knockout is consistent with the phenotypes of the respective mice, both mutations fail to  
2 fully recapitulate the bone, cartilage and fat abnormalities of the global *Mmp14*<sup>-/-</sup> mouse,  
3 which has osteopenia, lipodystrophy and arthritis. These discrepancies indicate that MT1-  
4 MMP controls SSC differentiation by both proteolytic and non-proteolytic mechanisms,  
5 and the balance of these two functions is required for normal differentiation. MT1-MMP-  
6 mediated ECM degradation modulates mechanosignaling that controls gene expression  
7 during SSC differentiation into osteoblasts, and conditional *Mmp14* deficiency in SSC  
8 blocks osteogenesis and causes severe osteopenia (Y. Tang et al., 2013). Normal SSC  
9 differentiation requires the concerted action of ECM remodeling and intracellular  
10 signaling, cell functions modulated by the extracellular environment. *In vitro*, in the  
11 presence of abundant ECM - such as in collagen gel culture (Y. Tang et al., 2013) – the  
12 proteolytic activity of MT1-MMP is indispensable. Conversely, in the presence of relatively  
13 low amounts of ECM – such as in 2D culture – the role of intracellular signaling becomes  
14 prevalent. *In vivo*, cell differentiation in the stem cell niche, tissue/organ development and  
15 remodeling have different proteolytic and signaling requirements, which are spatially and  
16 temporally modulated.

17 The relative contribution of proteolysis and signaling to MT1-MMP function is also  
18 coordinated by extracellular ligands that can inhibit extracellular MT1-MMP proteolytic  
19 activity and activate intracellular signaling. This hypothesis is supported by our previous  
20 finding that TIMP-2 binding to MT1-MMP activates ERK1/2 and Akt signaling (D'Alessio  
21 et al., 2008; Valacca et al., 2015), as well as by the observation that in the mouse embryo  
22 MT1-MMP is temporally and spatially co-expressed with TIMP-2 in the developing  
23 skeleton (Apte et al., 1997; Kinoh et al., 1996). *TIMP-2*<sup>-/-</sup> mice do not display the severe  
24 phenotype of *Mmp14*<sup>-/-</sup> mice (Z. Wang et al., 2000). However, in these mice signaling can



1 be activated by MT1-MMP binding of TIMP-3 or TIMP-4, as well as a variety of  
2 extracellular and transmembrane proteins, including integrins and CD44, that  
3 physiologically interact with the MT1-MMP ectodomains (Mori et al., 2002; Zhao et al.,  
4 2004).

5 Thus, the loss of signaling function caused by the Y573D substitution (D'Alessio et  
6 al., 2008; Valacca et al., 2015) (Fig. 2 E) can be at the basis of the defects in SSC  
7 differentiation and the consequent phenotypes of the *Mmp14*<sup>Y573D/Y573D</sup> mouse. Studies  
8 by other groups, as well as our own (unpublished), have shown that, although ERK1/2  
9 signaling is important for osteoblast differentiation (Miraoui et al., 2009; Wu et al., 2015;  
10 Xiao et al., 2002), chronic inhibition of ERK1/2 activation results in increased SSC  
11 differentiation into osteoblasts (Ge et al., 2007; Higuchi et al., 2002; Nakayama et al.,  
12 2003; Schindeler & Little, 2006; Zhang et al., 2012); conversely, inhibition of PI3K/Akt  
13 signaling blocks adipo- and chondrogenesis (Kim & Chen, 2004; Lee et al., 2015; Li &  
14 Dong, 2016; Yang et al., 2011).

15 The molecular mechanism that relays signaling from the Y573 residue of the MT1-  
16 MMP cytoplasmic tail to the Ras-ERK1/2 and Ras-Akt pathways (D'Alessio et al., 2008;  
17 Valacca et al., 2015), remains to be investigated. The adaptor protein p130Cas, which  
18 binds to the cytoplasmic tail of MT1-MMP by a mechanism involving Y573 (Y. Wang &  
19 McNiven, 2012), recruits Src and/or focal adhesion kinase (FAK), which activate Ras  
20 (Bunda et al., 2014; Schlaepfer & Hunter, 1997). We speculate that TIMP-2 binding to  
21 MT1-MMP triggers the assembly of the p130Cas/Src/FAK complex at the MT1-MMP tail,  
22 and that this effect is abrogated by the Y573D substitution, which thus prevents the  
23 downstream activation of ERK1/2 and Akt signaling. In addition, Y573 could control

1 intracellular signaling by modulating cytoplasmic tail interactions with a variety of  
2 transmembrane or membrane-bound proteins including caveolin-1 (Annabi et al., 2001;  
3 Galvez et al., 2002; Galvez et al., 2004; Labrecque et al., 2004) and  $\beta$ 1 integrins or growth  
4 factor receptors (Langlois et al., 2007).

5 In conclusion, our findings provide the first *in vivo* evidence for an important role of  
6 MT1-MMP mediated, proteolysis-independent signaling in postnatal development and  
7 tissue homeostasis. Understanding the relative contribution of the proteolytic and  
8 signaling functions of MT1-MMP to the control of metabolic processes that affect a variety  
9 of tissues and organs will require the development of additional genetically engineered  
10 mouse models, as well as the molecular dissection of extracellular and intracellular  
11 components of the MT1-MMP signaling mechanism. The knowledge obtained from these  
12 studies can increase our understanding of the pathogenesis of important diseases that  
13 affect bone, cartilage and adipose tissue homeostasis, such as osteopenia, osteoarthritis  
14 and obesity, and potentially direct the design of novel pharmacological tools for their  
15 treatment.

16

## 1 MATERIALS AND METHODS

### 2 ***Generation of MT1-MMP Y573D mice***

3 To generate a mouse with the Y573D mutation in the MT1-MMP cytoplasmic tail we  
4 constructed a targeting vector as described in Figure 1 A. The construct was  
5 electroporated into W4 embryonic stem (ES) cells, followed by G418 and gancyclovir  
6 double selection. The W4 cells were provided to us by the Rodent Genetic Engineering  
7 of NYU School of Medicine, who carried out the blastocysts injections and subsequent  
8 procedures. Homologous recombination targeting events were identified in 8 ES cell  
9 colonies. Two of these, devoid of chromosome abnormalities by cytogenetic analysis,  
10 were used for injection into blastocysts of C57BL/6 mice (C57BL/6NTac; Taconic), and  
11 one gave germline transmission. Mice heterozygote for the mutation (*Mmp14*<sup>Y573/wt</sup>),  
12 identified by PCR analysis with primers flanking the *LoxP* sites (Fig. 1 A), were crossed  
13 with Rosa26Cre Deleter mice (C57BL/6NTac-*Gt(ROSA)26Sor*<sup>tm16(cre)Arte</sup>; Taconic) to  
14 excise the neo cassette. Homozygote *Mmp*<sup>Y573D/Y573D</sup> mice were generated by  
15 heterozygote mating, and crossed back to wt C57BL/6 mice to remove the Cre  
16 recombinase gene. Sequencing of MT1-MMP cDNA from *Mmp*<sup>Y573D/Y573D</sup> mouse tissue  
17 showed identity with wt MT1-MMP except for the Y573D mutation. Heterozygote mating  
18 produced wt, heterozygote and homozygote mice in the expected Mendelian ratios. The  
19 mice were genotyped by PCR using the same primers flanking the *loxP sites*, which afford  
20 identification of the three genotypes (Fig. 1 B). The sequences of these primers are:

21 Forward: GCT TGG CAG AGT GGA AAG AC

22 Reverse: GGG CAG TGA TGA AGG TGA GT

1 All the animal studies were carried out in strict accordance with the recommendations in  
2 the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.  
3 All procedures were approved by the Institutional Animal Care and Use Committee  
4 (IACUC) of New York University School of Medicine.

### 5 ***Preparation of bone sections for histological analysis***

6 Mice were euthanized by carbon dioxide narcosis, and the entire limb was removed  
7 by excising the femur at the joint in the upper extremity of the hip socket and the tibia at  
8 the ankle. The remaining skin was peeled off and the connective tissue removed. Limbs  
9 were placed in cold 4% paraformaldehyde for 24 h, and decalcified by incubation with  
10 Immunocal<sup>™</sup> (Decal Corporation, Tallman, NY) or 10% EDTA for 72 h, with the  
11 decalcifying solution replaced with fresh one daily. Following decalcification, the limbs  
12 were rinsed 4 times for 30 min in PBS, 30 min in 0.85% NaCl and dehydrated for 30 min  
13 in 50% and 70% ethanol. Samples were embedded in paraffin blocks and sequentially  
14 cut into 5- $\mu$ m sections, mounted onto slides and stained with the indicated reagents.

### 15 ***Immunohistochemistry***

16 Paraffin-embedded specimens of brown adipose tissue (BAT) were cut and  
17 immunostained with antibody to uncoupling protein-1 UCP-1 (R&D Systems, cat. #  
18 MAB6158, Minneapolis, MN) at a concentration of 10  $\mu$ g/mL by personnel of the  
19 Experimental Pathology Core of NYU School of Medicine. The antibody was validated  
20 using, as a negative control, sections of subcutaneous WAT devoid of BAT (Fig. 7 – figure  
21 supplement 2).

22

23

## 1 **Western blotting**

2 Western blotting analysis was done as described (D'Alessio et al., 2008; Valacca et  
3 al., 2015) using the following antibodies and predetermined dilutions/concentrations.  
4 MT1-MMP antibody: Anti-MMP14 antibody [EP1264Y] rabbit mAb (Abcam, cat. #  
5 ab51074; Cambridge, MA), dilution: 1:5,000; phospho-ERK1/2 antibody: Phospho-p44/42  
6 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) Rabbit mAb (Cell Signaling Technology, cat. #  
7 4377; Danvers, MA), dilution: 1:1,000; phospho-Akt antibody: Phospho-Akt (Ser473)  
8 (D9E) XP<sup>®</sup> Rabbit mAb (Cell Signaling Technology, cat. # 4060), dilution: 1:2,000; total  
9 ERK1/2 antibody: p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Cell Signaling  
10 Technology, cat. # 4695), dilution: 1:1,000; total Akt antibody: Akt (pan) (C67E7) Rabbit  
11 mAb (Cell Signaling Technologies, cat. # 4691), dilution: 1:1,000; anti-rabbit IgG antibody:  
12 Anti-rabbit IgG, HRP-linked Antibody (Cell Signaling Technologies, cat. # 7074), dilution:  
13 1:3,000.

## 14 **Micro-computed tomography (CT)**

15 Micro-CT was performed according to published guidelines (Bouxsein et al., 2010).  
16 Bones were scanned using a high-resolution SkyScan micro-CT system (SkyScan 1172,  
17 Kontich, Belgium). Images were acquired using a 10 MP digital detector, 10W energy  
18 (70kV and 142 mA), and a 0.5-mm aluminum filter with a 9.7- $\mu$ m image voxel size. A fixed  
19 global threshold method was used based on the manufacturer's recommendations and  
20 preliminary studies, which showed that mineral variation between groups was not high  
21 enough to warrant adaptive thresholds. The cortical region of interest was selected as the  
22 2.0-mm mid-diaphyseal region directly below the third trochanter. The trabecular bone  
23 was assessed as the 2.0-mm region at the distal femur metaphysis; measurements

1 included the bone volume relative to the total volume (BV/TV), bone mineral density  
2 (BMD), trabecular number (Tb.N), trabecular spacing (Tb.Sp), and trabecular thickness  
3 (Tb.Th).

#### 4 ***Isolation, culture and differentiation of BM SSC***

5 Cultures of BM SSC were established by a modification of the method described  
6 (Soleimani & Nadri, 2009). BM was flushed from cut femurs and tibiae using 3-ml syringes  
7 with Minimum Essential Medium Alpha ( $\alpha$ MEM without ribonucleosides or  
8 deoxyribonucleosides; Gibco, Life Technologies cat. # 12561-056, Grand Island, NY)  
9 supplemented with 15% fetal calf serum (FBS; Atlanta Biologicals, cat. # S11150, Flowery  
10 Branch, GA) and antibiotics (Penicillin-Streptomycin). After separating the BM into a  
11 single-cell suspension, the cells were passed through a 70- $\mu$ m cell strainer, incubated for  
12 2 min in NH<sub>4</sub>Cl red blood cell lysis solution (StemCell Technologies, cat. # 07800,  
13 Vancouver, Canada), and seeded into culture plates in  $\alpha$ MEM supplemented with 15%  
14 FBS and antibiotics. Three hours later non-adherent cells were removed by replacing the  
15 medium with fresh complete medium. This procedure was repeated twice a day for the  
16 first 72 h. Subsequently, the adherent cells were washed with phosphate buffer saline  
17 (PBS) and incubated with fresh medium every 3-4 days until the cultures became  
18 subconfluent. To induce differentiation the cells were seeded into 24-well plates ( $5 \times 10^4$   
19 cells/well). After 24 h, the culture medium was substituted with osteoblast or adipocyte  
20 differentiation medium, and incubation was continued for the indicated times, changing  
21 the medium with freshly prepared medium twice a week. For chondrocyte differentiation  
22 the cells were seeded into 48-well plates as a pellet ( $2.5 \times 10^5$  cells/well). The medium  
23 was substituted with freshly prepared differentiation medium 2 h after seeding, and

1 subsequently three times a week. Differentiation medium consisted of  $\alpha$ MEM  
2 supplemented with 10% FBS, penicillin/streptomycin and, for osteoblast differentiation:  
3 dexamethasone 1  $\mu$ M (Millipore Sigma, cat. # D4209; St. Louis, MO), beta-  
4 glycerolphosphate 20 mM (Millipore Sigma, cat. # 500200), L-ascorbic acid 50  $\mu$ M  
5 (Millipore Sigma, cat. # A5960); for adipocyte differentiation: dexamethasone 1  $\mu$ M,  
6 indomethacin 50  $\mu$ M (Millipore Sigma, cat. # I7378), 3-Isobutyl-1-methylxanthine (IBMX)  
7 500 nM (Millipore Sigma, cat. # I5879), insulin 5  $\mu$ g/ml (Millipore Sigma, cat. # I9278); and  
8 for chondrocyte differentiation: sodium pyruvate 100  $\mu$ g/ml, ascorbic acid 50  $\mu$ g/ml,  
9 dexamethasone 0.1  $\mu$ M, insulin, transferrin, selenium (ITS) mix 1X (Millipore Sigma, cat.  
10 # I3146) and bone morphogenetic protein-2 (BMP2) 300 ng/ml (Peprotech, cat. # 120-02-  
11 2UG, Rocky Hill, NJ). The SSC used for differentiation experiments were no older than  
12 passage 3 in culture.

### 13 ***CH310T1/2 cell culture, transfection and differentiation***

14 C3H10T1/2 cells obtained from the American Type Culture Collection (ATCC  
15 CLL226, Gaithersburg, MD) were grown in Dulbecco's MEM (DMEM; Gibco, Life  
16 Technologies, cat. # 10566-016) supplemented with 10% FCS (Atlanta Biologicals). Cells  
17 at 50-70% confluency were transfected by overnight incubation with the indicated cDNAs  
18 in complete growth medium using TransIT<sup>®</sup>-LT1 - Transfection Reagent according to the  
19 manufacturer's instructions (Mirus Bio, LLC, cat. # MIR2300; Madison, WI). Stable  
20 transfectants were selected in medium containing 500  $\mu$ g/ml hygromycin B (InvivoGen,  
21 cat. # ant-hg-1; San Diego, CA). Pools of resistant cell colonies were characterized for  
22 MT1-MMP expression by reverse transcription-PCR and Western blotting, and used for  
23 differentiation assays. To induce differentiation the cells were seeded into 24-well plates

1 at a density of  $2.5 \times 10^4$  cells/well and then shifted to DMEM with low glucose (1 g/L;  
2 Gibco, Life Technologies, cat. # 11885076) with the same FCS concentration and  
3 supplements used for BM-derived SSC differentiation.

#### 4 ***Quantitative PCR analysis of gene expression in differentiating cells***

5 Cells were lysed in Trizol Reagent (Invitrogen, Waltham, MA) and total RNA was  
6 isolated with RNeasy (Qiagen, Valencia, CA), according to the manufacturer's  
7 instructions. RNA was quantified using a Nanodrop 2000 spectrophotometer  
8 (ThermoFisher Scientific, Waltham, MA), and 1  $\mu$ g of total RNA was used for cDNA  
9 preparation using SuperScript III (Invitrogen, Life Technologies). Quantitative real-time  
10 PCR reactions were performed with SYBR green PCR reagents using the ABI Prism 7300  
11 sequence detection system (Applied Biosystems-Life Technologies, Waltham, MA).  
12 Relative gene expression levels were calculated using the 2 delta Ct method (Livak &  
13 Schmittgen, 2001). Target mRNA levels were normalized to the geomean of  
14 Supplementary File 1.

#### 15 ***Analysis of circulating hormones and cytokines***

16 Serum and/or plasma levels of the indicated hormones and cytokines were measured by  
17 multiplex ELISA kits (Millipore, Burlington, MA) at the High-Throughput Biology  
18 Laboratory of NYU School of Medicine.

#### 19 ***RNA-Seq and data analysis***

20 The indicated tissues and SSC were isolated from *Mmp14<sup>wt/wt</sup>* and *Mmp14<sup>Y573D/Y573</sup>* mice  
21 (3 mice/tissue/genotype) and total RNA was extracted using the RNeasy kit (Qiagen).  
22 The subsequent steps were carried out by personnel of the Genome Technology Center of



1 NYU School of Medicine. RNA-Seq libraries were prepared with the TruSeq sample  
2 preparation kit (Illumina, San Diego, CA). Sequencing reads were mapped to the mouse  
3 genome using the STAR aligner (v2.5.0c) (Dobin et al., 2013). Alignments were guided  
4 by a Gene Transfer Format file (Ensembl GTF version GRCh37.70). The mean read insert  
5 sizes and their standard deviations were calculated using Picard tools (v.1.126). Read  
6 count tables were generated using HTSeq (v0.6.0) (Anders et al., 2015), normalized to  
7 their library size factors with DESeq (v3.7) (Anders & Huber, 2010), and differential  
8 expression analysis was performed. Read Per Million (RPM) normalized BigWig files  
9 were generated using BEDTools (v2.17.0) (Quinlan & Hall, 2010) and  
10 bedGraphToBigWig tool (v4). Statistical analyses were performed with R (v3.1.1), GO  
11 analysis with David Bioinformatics Resources 6.8 (Huang da et al., 2009a, 2009b) and  
12 GSEA with the hallmarks (h.all.v6.1.symbols.gmt) gene sets of the Molecular Signature  
13 Database (MSigDB) v6.1 (Mootha et al., 2003; Subramanian et al., 2005).

#### 14 ***BM transplant***

15 Mice of 3 and 5 months of age were used for BM transplant experiments. The BM of  
16 female mice was transplanted into age-matched male mice. The recipient mice were  
17 lethally irradiated with a single dose of 9 Gy. Twenty-four hours later BM cells (BMCs)  
18 were collected from the tibias and femurs of donor mice, suspended in PBS containing  
19 2% heat-inactivated FBS, and  $5 \times 10^6$  BMCs in 200  $\mu$ l were injected into the recipient  
20 mice via the tail vein. Eight weeks later the mice were subjected to DEXA scanning  
21 analysis and then sacrificed. To verify BM engraftment we transplanted female mice with  
22 male BM, in order to characterize the recipients' BM by immunohistochemistry and/or flow  
23 cytometry with antibody to UTY, a Y chromosome marker (H. Wang et al., 2013).

1 However, several commercially available antibodies failed to recognize UTY in murine  
2 BM cells, probably because this marker is not expressed in these cells. For the same  
3 reasons we were not able to identify the genotype of transplanted animals' WAT or BAT  
4 by immunohistochemistry with UTY antibody, or RNA *in situ* hybridization. Therefore, we  
5 genotyped the BM of recipient mice for the *Mmp14*<sup>Y573D/Y573D</sup> mutation using the PCR  
6 primers designed for genotyping our mice. We reasoned that partial engraftment of  
7 donor's BM would result in both the *Mmp14*<sup>wt/wt</sup> and *Mmp14*<sup>Y573D/Y573D</sup> genotypes, with a  
8 pattern of PCR products identical to that of *Mmp14*<sup>Y573D/wt</sup> mice (Fig. 1 B). In addition,  
9 running the PCR reaction for a high number of cycles would afford detection of small  
10 residual amounts of BM from recipient mice. By this method, the results (Fig. 10 – figure  
11 supplement 1) showed virtually complete replacement of the recipient's BM with the  
12 donors' BM. However, we could not use this method to identify donor-derived adipocytes  
13 in the transplanted animals' WAT or BAT as these tissues contain circulating cells – e.g.  
14 macrophages – from the BM.

### 15 **Statistical analysis**

16 For the BM transplant experiments, to calculate the number of mice required in each  
17 group to achieve statistical significance for the expected differences between controls and  
18 experimental groups, we used the analysis of Power of Test based on the variance  
19 observed in our previous analyses of our mice. In our characterization of the bone,  
20 cartilage and fat phenotypes we found differences between MT1-MMP Y573D wt mice  
21 ranging 25% - 75% in the mean (m) values of the various parameters, with standard  
22 deviations (SD) ranging 25% - 50%. Therefore, we assumed m = 50% and SD = 35%. To  
23 calculate the number of animals needed we used the formula:  $n = (Z_a + Z_b)^2 \times 2 (\%SD)^2 /$   
24  $(\%D)^2$ , where: n is number of animals per group,  $(Z_a + Z_b)^2$  for a 2-Tailed test with power

1 of 90% at  $p=0.05$  is 10.5, %SD is the percent standard deviation, and %D is the assumed  
2 percent difference between control and experimental group(s). Thus,  $n = 10.5 \times 2(35)^2 /$   
3  $50^2 = 10.29$ . Therefore, we planned to use 11 mice for each experimental and control  
4 group. The statistical analysis of the results of all the experiments was performed with the  
5 two-tailed Student's t-test (unless otherwise indicated) using GraphPad Prism, Version  
6 7.05.

## 1 **ACKNOWLEDGMENTS**

2 We gratefully acknowledge the precious collaboration of the Rodent Genetic Engineering,  
3 High-Throughput Biology Laboratory, Experimental Pathology Research Laboratory, and  
4 Genome Technology Center of NYU School of Medicine, which are partially supported by  
5 NIH grant P30CA016087 to the Laura and Isaac Perlmutter Cancer Center and the  
6 Shared Instrumentation Grant S10 OD021747, and the MicroCT Core of NYU College of  
7 Dentistry, supported by NIH grant S10 OD010751 to Dr. Nicola C. Partridge.

8

## 1 **COMPETING INTERESTS**

2 The authors declare that they have no financial or non-financial competing interests.

3 .

## 1 REFERENCES

- 2 Anders, S., & Huber, W. (2010). Differential expression analysis for sequence count data.  
3 *Genome Biol*, 11(10), R106. doi:10.1186/gb-2010-11-10-r106
- 4 Anders, S., Pyl, P. T., & Huber, W. (2015). HTSeq--a Python framework to work with high-  
5 throughput sequencing data. *Bioinformatics*, 31(2), 166-169.  
6 doi:10.1093/bioinformatics/btu638
- 7 Annabi, B., Lachambre, M., Bousquet-Gagnon, N., Page, M., Gingras, D., & Beliveau, R.  
8 (2001). Localization of membrane-type 1 matrix metalloproteinase in caveolae  
9 membrane domains. *Biochem J*, 353(Pt 3), 547-553.
- 10 Annabi, B., Laflamme, C., Sina, A., Lachambre, M. P., & Beliveau, R. (2009). A MT1-  
11 MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in  
12 CD133+ U87 glioblastoma cells. *J Neuroinflammation*, 6, 8. doi:10.1186/1742-  
13 2094-6-8
- 14 Apte, S. S., Fukai, N., Beier, D. R., & Olsen, B. R. (1997). The matrix metalloproteinase-  
15 14 (MMP-14) gene is structurally distinct from other MMP genes and is co-  
16 expressed with the TIMP-2 gene during mouse embryogenesis. *The Journal of*  
17 *biological chemistry*, 272(41), 25511-25517.
- 18 Belkaid, A., Fortier, S., Cao, J., & Annabi, B. (2007). Necrosis induction in glioblastoma  
19 cells reveals a new "bioswitch" function for the MT1-MMP/G6PT signaling axis in  
20 proMMP-2 activation versus cell death decision. *Neoplasia*, 9(4), 332-340.
- 21 Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J., & Muller,  
22 R. (2010). Guidelines for assessment of bone microstructure in rodents using  
23 micro-computed tomography. *J Bone Miner Res*, 25(7), 1468-1486.  
24 doi:10.1002/jbmr.141

- 1 Bunda, S., Heir, P., Srikumar, T., Cook, J. D., Burrell, K., Kano, Y., Lee, J. E., Zadeh, G.,  
2 Raught, B., & Ohh, M. (2014). Src promotes GTPase activity of Ras via tyrosine  
3 32 phosphorylation. *Proc Natl Acad Sci U S A*, 111(36), E3785-3794.  
4 doi:10.1073/pnas.1406559111
- 5 Chun, T. H., Hotary, K. B., Sabeh, F., Saltiel, A. R., Allen, E. D., & Weiss, S. J. (2006). A  
6 pericellular collagenase directs the 3-dimensional development of white adipose  
7 tissue. *Cell*, 125(3), 577-591. doi:10.1016/j.cell.2006.02.050
- 8 Chun, T. H., & Inoue, M. (2014). 3-D adipocyte differentiation and peri-adipocyte collagen  
9 turnover. *Methods Enzymol*, 538, 15-34. doi:10.1016/B978-0-12-800280-3.00002-  
10 5
- 11 Chun, T. H., Inoue, M., Morisaki, H., Yamanaka, I., Miyamoto, Y., Okamura, T., Sato-  
12 Kusubata, K., & Weiss, S. J. (2010). Genetic link between obesity and MMP14-  
13 dependent adipogenic collagen turnover. *Diabetes*, 59(10), 2484-2494.  
14 doi:10.2337/db10-0073
- 15 Clarke, B. (2008). Normal bone anatomy and physiology. *Clin J Am Soc Nephrol*, 3 Suppl  
16 3, S131-139. doi:10.2215/CJN.04151206
- 17 Crossno, J. T., Jr., Majka, S. M., Grazia, T., Gill, R. G., & Klemm, D. J. (2006).  
18 Rosiglitazone promotes development of a novel adipocyte population from bone  
19 marrow-derived circulating progenitor cells. *J Clin Invest*, 116(12), 3220-3228.  
20 doi:10.1172/JCI28510
- 21 D'Alessio, S., Ferrari, G., Cinnante, K., Scheerer, W., Galloway, A. C., Roses, D. F.,  
22 Rozanov, D. V., Remacle, A. G., Oh, E. S., Shiryayev, S. A., Strongin, A. Y.,  
23 Pintucci, G., & Mignatti, P. (2008). Tissue inhibitor of metalloproteinases-2 binding  
24 to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell

- 1 growth by a non-proteolytic mechanism. *J Biol Chem*, 283(1), 87-99.  
2 doi:M705492200 [pii]  
3 10.1074/jbc.M705492200
- 4 Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P.,  
5 Chaisson, M., & Gingeras, T. R. (2013). STAR: ultrafast universal RNA-seq  
6 aligner. *Bioinformatics*, 29(1), 15-21. doi:10.1093/bioinformatics/bts635
- 7 Dreier, R., Grassel, S., Fuchs, S., Schaumburger, J., & Bruckner, P. (2004). Pro-MMP-9  
8 is a specific macrophage product and is activated by osteoarthritic chondrocytes  
9 via MMP-3 or a MT1-MMP/MMP-13 cascade. *Exp Cell Res*, 297(2), 303-312.  
10 doi:10.1016/j.yexcr.2004.02.027
- 11 Evans, B. R., Mosig, R. A., Lobl, M., Martignetti, C. R., Camacho, C., Grum-Tokars, V.,  
12 Glucksman, M. J., & Martignetti, J. A. (2012). Mutation of membrane type-1  
13 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis  
14 disease Winchester syndrome. *Am J Hum Genet*, 91(3), 572-576.  
15 doi:10.1016/j.ajhg.2012.07.022
- 16 Feinberg, T. Y., Rowe, R. G., Saunders, T. L., & Weiss, S. J. (2016). Functional roles of  
17 MMP14 and MMP15 in early postnatal mammary gland development.  
18 *Development*, 143(21), 3956-3968. doi:10.1242/dev.136259
- 19 Fenech, M., Gavrilovic, J., Malcolm, P., Toms, A., & Turner, J. (2015). The role of  
20 metalloproteinases and their tissue inhibitors in adipose tissue remodelling and  
21 whole-body lipid distribution: a cross-sectional clinical study. *Lancet*, 385 Suppl 1,  
22 S36. doi:10.1016/S0140-6736(15)60351-8
- 23 Fenech, M., Gavrilovic, J., & Turner, J. (2015). Effect of tissue inhibitor of  
24 metalloproteinases 3 on DLK1 shedding in cultured human pre-adipocytes and



- 1           implications for adipose tissue remodelling. *Lancet*, 385 Suppl 1, S35.  
2           doi:10.1016/S0140-6736(15)60350-6
- 3 Galvez, B. G., Matias-Roman, S., Yanez-Mo, M., Sanchez-Madrid, F., & Arroyo, A. G.  
4           (2002). ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins  
5           at distinct cell compartments modulating its internalization and activity on human  
6           endothelial cells. *J Cell Biol*, 159(3), 509-521.
- 7 Galvez, B. G., Matias-Roman, S., Yanez-Mo, M., Vicente-Manzanares, M., Sanchez-  
8           Madrid, F., & Arroyo, A. G. (2004). Caveolae are a novel pathway for membrane-  
9           type 1 matrix metalloproteinase traffic in human endothelial cells. *Mol Biol Cell*,  
10          15(2), 678-687. doi:10.1091/mbc.E03-07-0516
- 11 Ge, C., Xiao, G., Jiang, D., & Franceschi, R. T. (2007). Critical role of the extracellular  
12          signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal  
13          development. *J Cell Biol*, 176(5), 709-718. doi:10.1083/jcb.200610046
- 14 Geyer, M., Grassel, S., Straub, R. H., Schett, G., Dinser, R., Grifka, J., Gay, S., Neumann,  
15          E., & Muller-Ladner, U. (2009). Differential transcriptome analysis of intraarticular  
16          lesional vs intact cartilage reveals new candidate genes in osteoarthritis  
17          pathophysiology. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research*  
18          *Society*, 17(3), 328-335. doi:10.1016/j.joca.2008.07.010
- 19 Gonzalo, P., Guadamillas, M. C., Hernandez-Riquer, M. V., Pollan, A., Grande-Garcia,  
20          A., Bartolome, R. A., Vasanji, A., Ambrogio, C., Chiarle, R., Teixido, J., Risteli, J.,  
21          Apte, S. S., del Pozo, M. A., & Arroyo, A. G. (2010). MT1-MMP is required for  
22          myeloid cell fusion via regulation of Rac1 signaling. *Developmental cell*, 18(1), 77-  
23          89. doi:10.1016/j.devcel.2009.11.012

- 1 Gupta, R. K., Mepani, R. J., Kleiner, S., Lo, J. C., Khandekar, M. J., Cohen, P., Frontini,  
2 A., Bhowmick, D. C., Ye, L., Cinti, S., & Spiegelman, B. M. (2012). Zfp423  
3 expression identifies committed preadipocytes and localizes to adipose endothelial  
4 and perivascular cells. *Cell Metab*, 15(2), 230-239.  
5 doi:10.1016/j.cmet.2012.01.010
- 6 Higuchi, C., Myoui, A., Hashimoto, N., Kuriyama, K., Yoshioka, K., Yoshikawa, H., & Itoh,  
7 K. (2002). Continuous inhibition of MAPK signaling promotes the early osteoblastic  
8 differentiation and mineralization of the extracellular matrix. *J Bone Miner Res*,  
9 17(10), 1785-1794. doi:10.1359/jbmr.2002.17.10.1785
- 10 Holmbeck, K., & al., e. (1999). MT1-MMP-deficient mice develop dwarfism, osteopenia,  
11 arthritis, and connective tissue disease due to inadequate collagen turnover. *Cell*,  
12 99(1), 81-92.
- 13 Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A.,  
14 Mankani, M., Gehron Robey, P., Robin Poole, A., Pidoux, I., Ward, J. M., &  
15 Birkedal-Hansen, H. (1999). MT1-MMP-Deficient Mice Develop Dwarfism,  
16 Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen  
17 Turnover. *Cell*, 99, 81–92.
- 18 Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009a). Bioinformatics enrichment  
19 tools: paths toward the comprehensive functional analysis of large gene lists.  
20 *Nucleic Acids Res*, 37(1), 1-13. doi:10.1093/nar/gkn923
- 21 Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009b). Systematic and integrative  
22 analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*, 4(1),  
23 44-57. doi:10.1038/nprot.2008.211

- 1 Itoh, Y. (2015). Membrane-type matrix metalloproteinases: Their functions and  
2 regulations. *Matrix Biol*, 44-46, 207-223. doi:10.1016/j.matbio.2015.03.004
- 3 Jevotovsky, D. S., Alfonso, A. R., Einhorn, T. A., & Chiu, E. S. (2018). Osteoarthritis and  
4 stem cell therapy in humans: a systematic review. *Osteoarthritis and cartilage /*  
5 *OARS, Osteoarthritis Research Society*, 26(6), 711-729.  
6 doi:10.1016/j.joca.2018.02.906
- 7 Karlsson, C., Dehne, T., Lindahl, A., Brittberg, M., Pruss, A., Sittering, M., & Ringe, J.  
8 (2010). Genome-wide expression profiling reveals new candidate genes  
9 associated with osteoarthritis. *Osteoarthritis and cartilage / OARS, Osteoarthritis*  
10 *Research Society*, 18(4), 581-592. doi:10.1016/j.joca.2009.12.002
- 11 Kevorkian, L., Young, D. A., Darrah, C., Donell, S. T., Shepstone, L., Porter, S.,  
12 Brockbank, S. M., Edwards, D. R., Parker, A. E., & Clark, I. M. (2004). Expression  
13 profiling of metalloproteinases and their inhibitors in cartilage. *Arthritis Rheum*,  
14 50(1), 131-141. doi:10.1002/art.11433
- 15 Kim, J. E., & Chen, J. (2004). Regulation of peroxisome proliferator-activated receptor-  
16 gamma activity by mammalian target of rapamycin and amino acids in  
17 adipogenesis. *Diabetes*, 53(11), 2748-2756.
- 18 Kinoh, H., Sato, H., Tsunozuka, Y., Takino, T., Kawashima, A., Okada, Y., & Seiki, M.  
19 (1996). MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is  
20 expressed with its substrate in mouse tissue during embryogenesis. *J Cell Sci*, 109  
21 ( Pt 5), 953-959.
- 22 Labrecque, L., Nyalendo, C., Langlois, S., Durocher, Y., Roghi, C., Murphy, G., Gingras,  
23 D., & Beliveau, R. (2004). Src-mediated tyrosine phosphorylation of caveolin-1

- 1 induces its association with membrane type 1 matrix metalloproteinase. *J Biol*  
2 *Chem*, 279(50), 52132-52140. doi:10.1074/jbc.M409617200
- 3 Lagoutte, E., Villeneuve, C., Lafanechere, L., Wells, C. M., Jones, G. E., Chavrier, P., &  
4 Rosse, C. (2016). LIMK Regulates Tumor-Cell Invasion and Matrix Degradation  
5 Through Tyrosine Phosphorylation of MT1-MMP. *Sci Rep*, 6, 24925.  
6 doi:10.1038/srep24925
- 7 Langlois, S., Nyalendo, C., Di Tomasso, G., Labrecque, L., Roghi, C., Murphy, G.,  
8 Gingras, D., & Beliveau, R. (2007). Membrane-Type 1 Matrix Metalloproteinase  
9 Stimulates Cell Migration through Epidermal Growth Factor Receptor  
10 Transactivation. *Mol Cancer Res*.
- 11 Lee, N., Kim, I., Park, S., Han, D., Ha, S., Kwon, M., Kim, J., Byun, S. H., Oh, W., Jeon,  
12 H. B., Kweon, D. H., Cho, J. Y., & Yoon, K. (2015). Creatine inhibits adipogenesis  
13 by downregulating insulin-induced activation of the phosphatidylinositol 3-kinase  
14 signaling pathway. *Stem Cells Dev*, 24(8), 983-994. doi:10.1089/scd.2014.0130
- 15 Li, J., & Dong, S. (2016). The Signaling Pathways Involved in Chondrocyte Differentiation  
16 and Hypertrophic Differentiation. *Stem Cells Int*, 2016, 2470351.  
17 doi:10.1155/2016/2470351
- 18 Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using  
19 real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*, 25(4),  
20 402-408. doi:10.1006/meth.2001.1262
- 21 Miraoui, H., Oudina, K., Petite, H., Tanimoto, Y., Moriyama, K., & Marie, P. J. (2009).  
22 Fibroblast growth factor receptor 2 promotes osteogenic differentiation in  
23 mesenchymal cells via ERK1/2 and protein kinase C signaling. *J Biol Chem*,  
24 284(8), 4897-4904. doi:10.1074/jbc.M805432200

- 1 Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A., Sihag, S., Lehar, J.,  
2 Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., Houstis, N., Daly, M. J.,  
3 Patterson, N., Mesirov, J. P., Golub, T. R., Tamayo, P., Spiegelman, B., Lander,  
4 E. S., Hirschhorn, J. N., Altshuler, D., & Groop, L. C. (2003). PGC-1alpha-  
5 responsive genes involved in oxidative phosphorylation are coordinately  
6 downregulated in human diabetes. *Nat Genet*, *34*(3), 267-273.  
7 doi:10.1038/ng1180
- 8 Mori, H., Bhat, R., Bruni-Cardoso, A., Chen, E. I., Jorgens, D. M., Coutinho, K., Louie, K.,  
9 Bowen, B. B., Inman, J. L., Tecca, V., Lee, S. J., Becker-Weimann, S., Northen,  
10 T., Seiki, M., Borowsky, A. D., Auer, M., & Bissell, M. J. (2016). New insight into  
11 the role of MMP14 in metabolic balance. *PeerJ*, *4*, e2142. doi:10.7717/peerj.2142
- 12 Mori, H., Tomari, T., Koshikawa, N., Kajita, M., Itoh, Y., Sato, H., Tojo, H., Yana, I., &  
13 Seiki, M. (2002). CD44 directs membrane-type 1 matrix metalloproteinase to  
14 lamellipodia by associating with its hemopexin-like domain. *Embo J*, *21*(15), 3949-  
15 3959.
- 16 Nakayama, K., Tamura, Y., Suzawa, M., Harada, S., Fukumoto, S., Kato, M., Miyazono,  
17 K., Rodan, G. A., Takeuchi, Y., & Fujita, T. (2003). Receptor tyrosine kinases  
18 inhibit bone morphogenetic protein-Smad responsive promoter activity and  
19 differentiation of murine MC3T3-E1 osteoblast-like cells. *J Bone Miner Res*, *18*(5),  
20 827-835. doi:10.1359/jbmr.2003.18.5.827
- 21 Nyalendo, C., Michaud, M., Beaulieu, E., Roghi, C., Murphy, G., Gingras, D., & Beliveau,  
22 R. (2007). Src-dependent phosphorylation of membrane type I matrix  
23 metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell  
24 migration. *J Biol Chem*, *282*(21), 15690-15699.

- 1 Proulx-Bonneau, S., Guezzuez, A., & Annabi, B. (2011). A concerted HIF-1 $\alpha$ /MT1-  
2 MMP signalling axis regulates the expression of the 3BP2 adaptor protein in  
3 hypoxic mesenchymal stromal cells. *PLoS One*, 6(6), e21511.  
4 doi:10.1371/journal.pone.0021511
- 5 Quinlan, A. R., & Hall, I. M. (2010). BEDTools: a flexible suite of utilities for comparing  
6 genomic features. *Bioinformatics*, 26(6), 841-842.  
7 doi:10.1093/bioinformatics/btq033
- 8 Sakamoto, T., & Seiki, M. (2009). Cytoplasmic tail of MT1-MMP regulates macrophage  
9 motility independently from its protease activity. *Genes to cells : devoted to*  
10 *molecular & cellular mechanisms*, 14(5), 617-626. doi:10.1111/j.1365-  
11 2443.2009.01293.x
- 12 Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., & Seiki, M. (1994).  
13 A matrix metalloproteinase expressed on the surface of invasive tumour cells [see  
14 comments]. *Nature*, 370(6484), 61-65.
- 15 Schindeler, A., & Little, D. G. (2006). Ras-MAPK signaling in osteogenic differentiation:  
16 friend or foe? *J Bone Miner Res*, 21(9), 1331-1338. doi:10.1359/jbmr.060603
- 17 Schlaepfer, D. D., & Hunter, T. (1997). Focal adhesion kinase overexpression enhances  
18 ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase  
19 through interactions with and activation of c-Src. *J Biol Chem*, 272(20), 13189-  
20 13195.
- 21 Shimizu-Hirota, R., Xiong, W., Baxter, B. T., Kunkel, S. L., Maillard, I., Chen, X. W.,  
22 Sabeh, F., Liu, R., Li, X. Y., & Weiss, S. J. (2012). MT1-MMP regulates the  
23 PI3K $\delta$ .Mi-2/NuRD-dependent control of macrophage immune function. *Genes*  
24 *Dev*, 26(4), 395-413. doi:10.1101/gad.178749.111


- 1 Sina, A., Proulx-Bonneau, S., Roy, A., Poliquin, L., Cao, J., & Annabi, B. (2010). The  
2 lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2  
3 through an IKKgamma/NF-kappaB-dependent pathway. *J Cell Commun Signal*,  
4 4(1), 31-38. doi:10.1007/s12079-009-0084-0
- 5 Soleimani, M., & Nadri, S. (2009). A protocol for isolation and culture of mesenchymal  
6 stem cells from mouse bone marrow. *Nat Protoc*, 4(1), 102-106.  
7 doi:10.1038/nprot.2008.221
- 8 Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A.,  
9 Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., & Mesirov, J. P. (2005).  
10 Gene set enrichment analysis: a knowledge-based approach for interpreting  
11 genome-wide expression profiles. *Proc Natl Acad Sci U S A*, 102(43), 15545-  
12 15550. doi:10.1073/pnas.0506580102
- 13 Tang, Q. Q., Otto, T. C., & Lane, M. D. (2004). Commitment of C3H10T1/2 pluripotent  
14 stem cells to the adipocyte lineage. *Proc Natl Acad Sci U S A*, 101(26), 9607-9611.  
15 doi:10.1073/pnas.0403100101
- 16 Tang, Y., Rowe, R. G., Botvinick, E. L., Kurup, A., Putnam, A. J., Seiki, M., Weaver, V.  
17 M., Keller, E. T., Goldstein, S., Dai, J., Begun, D., Saunders, T., & Weiss, S. J.  
18 (2013). MT1-MMP-dependent control of skeletal stem cell commitment via a beta1-  
19 integrin/YAP/TAZ signaling axis. *Developmental cell*, 25(4), 402-416.  
20 doi:10.1016/j.devcel.2013.04.011
- 21 Tchetina, E. V., Squires, G., & Poole, A. R. (2005). Increased type II collagen degradation  
22 and very early focal cartilage degeneration is associated with upregulation of  
23 chondrocyte differentiation related genes in early human articular cartilage lesions.  
24 *J Rheumatol*, 32(5), 876-886.

- 1 Tran, K. V., Gealekman, O., Frontini, A., Zingaretti, M. C., Morroni, M., Giordano, A.,  
2 Smorlesi, A., Perugini, J., De Matteis, R., Sbarbati, A., Corvera, S., & Cinti, S.  
3 (2012). The vascular endothelium of the adipose tissue gives rise to both white  
4 and brown fat cells. *Cell Metab*, 15(2), 222-229. doi:10.1016/j.cmet.2012.01.008
- 5 Uekita, T., Itoh, Y., Yana, I., Ohno, H., & Seiki, M. (2001). Cytoplasmic tail-dependent  
6 internalization of membrane-type 1 matrix metalloproteinase is important for its  
7 invasion-promoting activity. *J Cell Biol*, 155(7), 1345-1356.
- 8 Valacca, C., Tassone, E., & Mignatti, P. (2015). TIMP-2 Interaction with MT1-MMP  
9 Activates the AKT Pathway and Protects Tumor Cells from Apoptosis. *PLoS One*,  
10 10(9), e0136797. doi:10.1371/journal.pone.0136797
- 11 Wang, H., Hu, Y. C., Markoulaki, S., Welstead, G. G., Cheng, A. W., Shivalila, C. S.,  
12 Pyntikova, T., Dadon, D. B., Voytas, D. F., Bogdanove, A. J., Page, D. C., &  
13 Jaenisch, R. (2013). TALEN-mediated editing of the mouse Y chromosome. *Nat*  
14 *Biotechnol*, 31(6), 530-532. doi:10.1038/nbt.2595
- 15 Wang, Y., & McNiven, M. A. (2012). Invasive matrix degradation at focal adhesions  
16 occurs via protease recruitment by a FAK-p130Cas complex. *J Cell Biol*, 196(3),  
17 375-385. doi:10.1083/jcb.201105153
- 18 Wang, Z., Juttermann, R., & Soloway, P. D. (2000). TIMP-2 is required for efficient  
19 activation of proMMP-2 in vivo. *J Biol Chem*, 275(34), 26411-26415.
- 20 Wu, Y., Zhou, J., Li, Y., Zhou, Y., Cui, Y., Yang, G., & Hong, Y. (2015). Rap1A Regulates  
21 Osteoblastic Differentiation via the ERK and p38 Mediated Signaling. *PLoS One*,  
22 10(11), e0143777. doi:10.1371/journal.pone.0143777
- 23 Xiao, G., Jiang, D., Gopalakrishnan, R., & Franceschi, R. T. (2002). Fibroblast growth  
24 factor 2 induction of the osteocalcin gene requires MAPK activity and




- 1 phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. *J Biol Chem*,  
2 277(39), 36181-36187. doi:10.1074/jbc.M206057200
- 3 Yang, H. J., Xia, Y. Y., Wang, L., Liu, R., Goh, K. J., Ju, P. J., & Feng, Z. W. (2011). A  
4 novel role for neural cell adhesion molecule in modulating insulin signaling and  
5 adipocyte differentiation of mouse mesenchymal stem cells. *J Cell Sci*, 124(Pt 15),  
6 2552-2560. doi:10.1242/jcs.085340
- 7 Zhang, M. Y., Ranch, D., Pereira, R. C., Armbrecht, H. J., Portale, A. A., & Perwad, F.  
8 (2012). Chronic inhibition of ERK1/2 signaling improves disordered bone and  
9 mineral metabolism in hypophosphatemic (Hyp) mice. *Endocrinology*, 153(4),  
10 1806-1816. doi:10.1210/en.2011-1831
- 11 Zhao, H., Bernardo, M. M., Osenkowski, P., Sohail, A., Pei, D., Nagase, H., Kashiwagi,  
12 M., Soloway, P. D., DeClerck, Y. A., & Fridman, R. (2004). Differential inhibition of  
13 membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue  
14 inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation.  
15 *J Biol Chem*, 279(10), 8592-8601.
- 16 Zhou, Z., Apte, S. S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., Wang, J.,  
17 Cao, Y., & Tryggvason, K. (2000). Impaired endochondral ossification and  
18 angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. *Proc*  
19 *Natl Acad Sci U S A*, 97(8), 4052-4057. doi:10.1073/pnas.060037197

20




**Figure 1. Generation of the MT1-MMP Y573D mouse.** **A.** Schematic representation of the targeting vector and targeted locus. To construct the targeting vector the genomic sequence of mouse MT1-MMP containing exons 2 to 10 was PCR amplified from W4 embryonic stem (ES) cells' DNA. A floxed neomycin resistance cassette (neo) was inserted into intron 9, adjacent to the 5' end of exon 10, which encodes Y573, and a *hsv*-thymidine kinase cassette (hsvtk) was placed at the 5' end of the construct. The TAC codon for Y573 was mutated into GAC by PCR. The construct was electroporated into W4 ES cells and colonies of recombinant cells were selected as described in Materials and Methods. The red X indicates the Y573D substitution; B: BamHI; C: ClaI; E: EcoRI; N: NotI; S: Sall; X: XhoI. **B.** PCR genotyping. The mice were genotyped by PCR using primers flanking the *loxP* sites, which afford identification of the three genotypes. The sequence of the primers is reported in Materials and Methods.



**Figure 2. Phenotypic characterization of the MT1-MMP Y573D mouse.** **A.** Growth curve of *Mmp14*<sup>wt/wt</sup> (▲), *Mmp14*<sup>wt/Y573D</sup> (▼) and (*Mmp14*<sup>Y573D/Y573D</sup> (●) littermates. **B.** Body mass of 5- to 7-month old *Mmp14*<sup>wt/wt</sup> (wt/wt; n = 14) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD; n = 15) mice of both sexes (33.54 ± 1.44 g vs. 28.5 ± 1.15 g, respectively). \*: p ≤ 0.001. **C.** Western blotting analysis of MT1-MMP in kidney and lungs from *Mmp14*<sup>wt/Y573D</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) littermates. MT1-MMP control: extracts of MT1-MMP-transfected MCF-7 cells (D'Alessio et al., 2008). Beta-actin is shown in the lower panel as a loading control. This experiment was repeated twice with comparable results. **D.** Gelatin zymographic analysis of proMMP-2 activation in the serum-free conditioned medium of primary cultures of *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) mouse fibroblasts incubated with exogenous human recombinant proMMP-2 for 16 h. Before zymography the conditioned medium was incubated in the absence or presence (+) of APMA (1 mM in DMSO) for 1.5 h at 37° C as a positive control for proMMP-2 activation. This experiment was repeated three times with comparable results. **E.** Western blotting analysis of ERK1/2 and Akt activation (p-ERK1/2 and p-Akt) in primary fibroblasts from *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) adult mice, incubated with human recombinant TIMP-2 (100 ng/ml) or an equivalent volume of control vehicle for 15 min. Total ERK1/2 and Akt protein is shown as a loading control. Equal protein amounts of cell extracts were run in two separate gels and transferred onto separate membranes, one of which was probed with antibodies to the phospho-ERK1/2 and phospho-Akt, and the other to total ERK1/2 and Akt. This experiment was performed three times with similar results.







**Figure 3 – with 1 supplement. MT1-MMP Y573D mice show decreased cortical bone and increased trabecular bone. A and B.** MicroCT analysis of cortical (A) and trabecular bone (B) from *Mmp14*<sup>wt/wt</sup> (wt/wt; n = 3) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD; n= 3) 2-month old mice. Upper panels; 3D reconstruction; lower panels: quantitative analysis. **A.** BV/TV: bone volume/tissue volume; \*: p = 0.0067; Cs. Th.: cortical thickness; \*\*p = 0.0009; M. Ar.: bone marrow area; \*\*\* p = 0.0524. **B.** BV: bone volume; †: p = 0.0115; BV/TV: bone volume/tissue volume; #: p = 0.0366; Tb. Th.: trabecular thickness; X: p = 0.0290. **C.** Representative sections of the femurs of *Mmp14*<sup>wt/wt</sup> (wt/wt), *Mmp14*<sup>Y573D/wt</sup> (wt/YD) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) 2-month old mice. H&E staining; original magnification: 4X. **D.** Osteomeasure analysis of trabecular bone in femurs (blue bars) and tibiae (red bars) of the mice shown in panel C. Mean ± s.d. of 5 mice/group are shown. BV/TV: bone volume / total volume; \*: p = 0.0329; \*\*: p = 0.0012; #: p = 0.0489. Tb. N.: number of trabeculae; \*: p = 0.0425; \*\*: p = 0.0021; #: p = 0.0018. Tb. Th.: trabecular thickness; \*: p = 0.0478; \*\*: p = 0.0018; #: p = 0.0089. Tb. Sp.: space between trabeculae; \*: p = 0.0014; \*\*: p = 0.0019; #: p = 0.0197 (sample vs corresponding wt control). **E.** RNA seq analysis of differential gene expression in bone from *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice. Volcano plot representing genes with a significant (p ≤ 0.05) fold change higher than 2 (red dots) or lower than -2 (green dots). **F.** GO analysis of pathways overrepresented in the bone of *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice.




# Figure 3 – figure supplement 1



wt/wt



wt/YD




YD/YD

bioRxiv preprint doi: <https://doi.org/10.1101/631739>; this version posted June 14, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.


**Figure 3 – figure supplement 1. Tartrate-resistant acid phosphatase (TRAP) staining of osteoclasts (dark red cells) in sections of the femurs of *Mmp14*<sup>wt/wt</sup> (wt/wt), *Mmp14*<sup>wt/Y573D</sup> (wt/YD) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) 2-month old mice. Original magnification: 4X**






**Figure 4. MT1-MMP Y573D mice show reduced thickness and structural abnormalities of articular cartilage.** Histological and histochemical analyses of knee joint cartilage from *Mmp14*<sup>wt/wt</sup> (wt/wt), *Mmp14*<sup>Y573D/wt</sup> (wt/YD) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) 2-month old mice. **A.** H&E staining; original magnification: top panels, 10X; bottom panels, 40X. White bars indicate the thickness of the cartilage at comparable locations in the joint. Arrows: chondrocyte cloning. **B.** Thickness of articular cartilage measured by Photoshop as shown in panel A (top panels) on multiple sections of knee joints of 3 mice per genotype. Mean  $\pm$  s.d. are shown. \*:  $p = 0.0004$ ; \*\*:  $p = 0.0001$ . **C.** Alcian blue staining, and **D.** Safranin O staining of sections of knee joints of 2-month old mice with the indicated genotypes. Original magnification: 20X and 10X, respectively. **E.** Histological sections of the shoulder (upper panels) and knee joints (lower panels) of 2-year old *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) mice. Red arrows point to cartilage erosion and fissures, and black arrows to chondrocytes oriented orthogonally to the cartilage surface, typical signs of cartilage degeneration. H&E staining; original magnification: 20X.





**Figure 5. The gene expression profile of the articular cartilage of *Mmp14*<sup>Y573D/Y573D</sup> mice shows similarity to that of human OA. A.** RNA seq analysis of differential gene expression in articular cartilage from *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice. Volcano plot representing genes with a significant ( $p \leq 0.05$ ) fold change higher than 2 (red dots) or lower than -2 (green dots). **B.** GO analysis of pathways overrepresented in the articular cartilage of *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice. **C.** Venn diagram of differentially expressed genes in articular cartilage from *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice, and human OA cartilage vs. normal knee joint cartilage (Geyger et al., 2009; Karlsson et al., 2010). **D.** Gene families upregulated  $\geq 2$ -fold ( $p \leq 0.05$ ) in knee joint cartilage from both *Mmp14*<sup>Y573D/Y573D</sup> mice and OA patients.





**Figure 6 – with 2 supplements. MT1-MMP Y573D mice show decreased white adipose tissue. A and B.** Sections of the tibias of *Mmp14*<sup>wt/wt</sup> (wt/wt), *Mmp14*<sup>wt/Y573D</sup> (wt/YD) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) 4-month (A) or 2-years old mice (B). H&E staining; original magnification: 4X. **C.** DEXA scanning analysis of *Mmp14*<sup>wt/wt</sup> (wt/wt; n = 27) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD; n = 30) male and female, 7-month old mice. Mean ± s.d. are shown. \*: p = 0.0018, \*\*: p = 0.0295, #: p = 0.0177, †: p = 0.0230. Statistically significant percent differences between the two genotypes are indicated in the closed bars. **D.** Weight of abdominal fat normalized to total body weight of 2-, 4- and 7-month old, *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) male and female mice; p = 0.0001.



## Figure 6 – figure supplement 1





Figure 6 – figure supplement 1. DEXA scanning analysis of lean and fat body mass of 4-month old *Mmp14*<sup>wt/wt</sup> (wt/wt; n = 10) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD; n = 10) female mice. Mean ± s.d. are shown. Statistically significant percent differences between the two genotypes are indicated in the closed bars. \*: p = 0.0121; \*\*: p = 0.0060; #: p = 0.0093; ¶: p = 0.0124.


## Figure 6 – figure supplement 2

### Fat percent



**Figure 6 – figure supplement 2. DEXA scanning analysis of adipose tissue in 10-weeks old *Mmp14*<sup>wt/wt</sup> (wt/wt; n = 10) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD; n = 10) male or female mice. Mean ± s.d. are shown. Statistically significant percent differences between the two genotypes are indicated in the closed bars. \*: p = 0.0001; \*\*: p = 0.0044.**






**Figure 7 – with 3 supplements. MT1-MMP Y573D mice have hypotrophic white fat and hypertrophic brown fat. A.** H&E stained sections of periepididymal (left panels; 10X) and subcutaneous fat (right panels; 20X) of *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) mice. **B.** Sections of infrascapular brown fat from *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) mice, immunostained with antibody to UCP-1. Original magnification: 1.66X, left panels; 20X, right panels. **C.** Adipocyte size of periepididymal fat from *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) mice. The area of individual adipocytes was measured by Photoshop using multiple sections (5 mice/genotype) of periepididymal fat similar to those shown in A (left panels). Mean  $\pm$  s.d. are shown. \*  $p = 0.0003$ . **D.** RNA seq analysis of differential gene expression in articular cartilage from *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice. Volcano plot representing genes with a significant ( $p \leq 0.05$ ) fold change higher than 2 (red dots) or lower than -2 (green dots). **E.** GO analysis of pathways overrepresented in white adipose tissue of *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice.




# Figure 7 – figure supplement 1



**Figure 7 – figure supplement 1. Histological sections of subcutaneous fat in *Mmp14*<sup>wt/wt</sup> (wt/wt; left column) and *Mmp14*<sup>Y573D/Y573D</sup> mice (YD/YD; right column). H&E staining; original magnification: 20X. Age- and sex-matched mice are shown on the same row. *Mmp14*<sup>Y573D/Y573D</sup> mice show hypotrophic adipocytes and reduced thickness of the adipose layer.**




## Figure 7 – figure supplement 2




**Figure 7 – figure supplement 2.** Histological sections of brown fat from *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> mice (YD/YD), immunostained with antibody to UCP-1. Control: section of subcutaneous white fat from a wt mouse, immunostained with UCP-1 antibody using the same protocol as for the brown fat sections. Original magnification: 1.66X, left panels; 20X, right panels.

## Figure 7 – figure supplement 3




**Figure 8 – figure supplement 1. Weight gain analysis of 6-week old *Mmp14*<sup>wt/wt</sup> (wt/wt; n = 2) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD; n = 2) littermates fed normal chow or a high-fat diet. The regression curves and the statistical significance of their differences were calculated with GraphPad Prism, Version 7.05.**



**Figure 8 – with 1 supplement. MT1-MMP Y573D mice have low levels of insulin and inflammatory cytokines.** Analysis of circulating hormones and cytokines in 4-month old *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) mice. Mean  $\pm$  s.d. are shown. \*:  $p = 0.023$ ; \*\*:  $p = 0.0001$ ; \*\*\*:  $p = 0.0024$ ; \*\*\*\*:  $p = 0.0384$ .




# Figure 8 – figure supplement 1



**Figure 8 – figure supplement 2. Fasting serum levels of insulin and glucose in, and food consumption by, *Mmp14*<sup>wt/wt</sup> (wt/wt; n = 8) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD; n = 8) mice.** The graph of insulinemia is the same as that shown in Fig. 10, and is shown here for comparison with glycemia. \*: p = 0.0203.


bioRxiv preprint doi: <https://doi.org/10.1101/631739>; this version posted June 14, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.





**Figure 9. MT1-MMP Y573D expression impairs SSC proliferation and survival, and skews differentiation towards osteogenesis.** **A.** CFU-F of *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) SSC; Giemsa staining. This experiment was repeated twice with similar results. **B.** MTS assay of cells grown for 48 h. \*  $p = 0.0001$ . This experiment was repeated three times with similar results. **C.** Percentage of apoptotic nuclei in DAPI stained cells (298 – 320 nuclei). \*  $p = 0.001$ . This experiment was repeated twice with similar results. **D.** RNA seq analysis of differential gene expression in articular cartilage from *Mmp14*<sup>Y573D/Y573D</sup> vs. *Mmp14*<sup>wt/wt</sup> mice. Volcano plot representing genes with a significant ( $p \leq 0.05$ ) fold change higher than 2 (red dots) or lower than -2 (green dots). **E.** GO analysis of pathways overrepresented in BM-derived SSC from *Mmp14*<sup>wt/wt</sup> (wt/wt) and *Mmp14*<sup>Y573D/Y573D</sup> (YD/YD) mice. **F.** qPCR analysis of osteoblast (top), chondrocyte (middle) and adipocyte markers (bottom panel) in BM-derived SSC from *Mmp14*<sup>wt/wt</sup> (open bars) and *Mmp14*<sup>Y573D/Y573D</sup> (solid bars) 4-month old littermates, after 17 days in osteoblast or chondrocyte or adipocyte differentiation medium. Shown are mean  $\pm$  s.d. of data normalized to geomean of GAPDH and HPRT1 for the three cell types. \*:  $p \leq 0.05$ . This experiment was repeated twice with similar results. **G.** Differentiation of C3H10T1/2 cells stably transfected with wt or MT1-MMP Y573D cDNA. Top panel, osteogenesis: Alizarin red staining of cells after 21 days in osteoblast differentiation medium. Middle panel, chondrogenesis: Alcian blue staining of cell pellets after 21 days in chondrocyte differentiation medium (original magnification: 4X). Bottom panel, adipogenesis: oil red O staining of cells grown in adipocyte differentiation medium for 7 days (original magnification: 10X). This experiment was repeated three times with similar results.







**Figure 10 - with 1 supplement. wt BM transplant rescues the trabecular bone phenotype of MT1-MMP Y573D mice.** MicroCT 3D reconstruction (upper panels) and quantitative measurements (lower panels) of cortical bone of *Mmp14*<sup>wt/wt</sup> mice transplanted with BM from *Mmp14*<sup>Y573D/Y573D</sup> mice (YD►wt) or *Mmp14*<sup>Y573D/Y573D</sup> mice transplanted with *Mmp14*<sup>wt/wt</sup> BM (wt►YD). Mice transplanted with BM of the same genotype (wt►wt and YD►YD) were used as controls. The mice (n = 9-11/group) were transplanted at 3 months of age, and analyzed 2 months later. BV/TV: bone volume normalized to total tissue volume; Cs. Th.: cortical thickness; Ma. Ar.: bone marrow area. The YD►YD samples show ~ 20% reduced cortical bone relative to wt ► wt samples, as expected (Fig. 1 A); wt ► YD or YD►wt BM transplant does not change the phenotype of the recipient. Mean ± s.d. are shown. \*: p = 0.0003; \*\*: p = 0.0021; ‡: p = 0.0038. **B.** MicroCT 3D reconstruction (upper panels) and quantitative measurements (lower panels) of trabecular bone of the mice described in A. The YD►YD samples show 35-40% increase in trabecular bone relative to wt ► wt samples, as expected (Fig. 1 B); *Mmp14*<sup>wt/wt</sup> BM transplant lowers the amount of trabecular bone in *Mmp14*<sup>Y573D/Y573D</sup> mice to a level similar to that of the wt►wt controls (dotted line). Conversely, BM transplant from *Mmp14*<sup>Y573D/Y573D</sup> mice does not transfer the phenotype to *Mmp14*<sup>wt/wt</sup> mice. BV/TV: bone volume normalized to total tissue volume; Tb. N. trabecular number / mm; Tb. Th.: trabecular thickness. Mean ± s.d. are shown. \*: p = 0.047; \*\*: p = 0.0150; ‡: p = 0.0124; †: p = 0.0397; ‡: p = 0.0117.

# Figure 10 – figure supplement 1

## Cortical bone




## Trabecular bone



**Figure 10 – figure supplement 1.** Quantitative microCT analysis of cortical and trabecular bone of 5-month mice (n = 9-11/group) transplanted as described in the legends to Figs. 13 and 14. The mice (n = 9-11/group) were transplanted at 5 months of age, and analyzed 2 months later. The results are comparable to those presented in Figs. 13 and 14. X: p = 0.002; ¥: p = 0.0002; \*: p = 0.005; ll: p = 0.0323; †: p = 0.0362; ¯: p = 0.0025; ¨: p = 0.0162.






**Figure 11 - with 1 supplement. A. wt BM transplant rescues the adipose tissue phenotype of MT1-MMP Y573D mice.** Weight of visceral fat normalized to total weight of the mice ( $n = 9-11/\text{group}$ ) described in Fig. 8, transplanted at 3 or 5 months of age and analyzed 2 months later. The YD $\blacktriangleright$ YD samples show  $\sim 50\%$  less fat than age-matched wt $\blacktriangleright$ wt controls, as expected (Fig. 4). *Mmp14*<sup>wt/wt</sup> BM transplant increases the amount of adipose tissue in *Mmp14*<sup>Y573D/Y573D</sup> mice to a level similar to that of the wt $\blacktriangleright$ wt controls (dotted line). Conversely, BM transplant from *Mmp14*<sup>Y573D/Y573D</sup> mice does not reduce the fat mass in *Mmp14*<sup>wt/wt</sup> mice. Mean  $\pm$  s.d. are shown. \*:  $p = 0.006$ ; ‡:  $p = 0.008$ ; †:  $p = 0.003$ ; ‡:  $p = 0.001$ . **B and C. WAT and BAT of BM-transplanted mice show a mixture of donor and recipient phenotypes.** Histological sections of periepididymal WAT (**A**) and infrascapular BAT (**B**) of the mice described in Fig. 8. H&E staining; original magnification: A, 10X; B, 20X. The YD $\blacktriangleright$ YD samples show hypotrophic white adipocytes (A) and hypertrophic brown adipocytes, as expected (Fig. 5 B and C); wt  $\blacktriangleright$  YD or YD $\blacktriangleright$  wt BM transplant results in a mixture of normal and hypotrophic white adipocytes (A), and in recipient mice acquiring the BAT phenotype of the donors.



# Figure 11 – figure supplement 1



**Figure 10 – figure supplement 1. PCR genotyping of BM from mice transplanted with BM as indicated (YD►wt: *Mmp14*<sup>wt/wt</sup> mice transplanted with BM from *Mmp14*<sup>Y573D/Y573D</sup> mice; wt►YD: *Mmp14*<sup>Y573D/Y573D</sup> mice transplanted with *Mmp14*<sup>wt/wt</sup> BM. BM from non-transplanted *Mmp14*<sup>wt/wt</sup> mice (wt) or *Mmp14*<sup>Y573D/Y573D</sup> mice (YD) is shown as control. The PCR genotyping of non-transplanted mice with the three genotypes shown in the right panel is the same as shown in Figure 1 B, and is reported here to illustrate the expected pattern of BM with a mixed *Mmp14*<sup>wt/wt</sup> and *Mmp14*<sup>Y573D/Y573D</sup> genotype.**